

# LEMTRADA

# UX documentation

19.Nov.2014

Contents

2	SITEMAP
3	WIREFRAMES : mobile
4	MOBILE header / footer
5	MOBILE menu
6	M 0.0 Home
7	M 1.1 Why Lemtrada
8	M 1.1 Why Lemtrada / fewer relapses - slower brain atrophy
9	M 1.1 Why Lemtrada / (clinical case study opened)
10	M 1.1 Why Lemtrada / innovative treatment schedule
11	M 1.2 : How Lemtrada works
12	M 1.3 : Safety & Monitoring
13	M 1.4 : Talking to your Doctor
14	M 1.5 : FAQs
15	M 2.1 Treatment Steps
16	M 2.1 Treatment Steps / detail
17	M 2.2 Care Partner Tips
18	M 3.1 Lemtrada Events
19	M 3.2 Registration
20	M 3.2 Registration - confirmation
21	M 3.3 Events
22	M 3.3 Events : event detail
23	M 3.4 Helpful Resources
24	M F.1 Sitemap
25	WIREFRAMES : desktop
26	HEADER AND FOOTER
27	DROP DOWN MENU
28	0.0 : Home
29	1.1 : Why Lemtrada, landing page
30	1.1 : Why Lemtrada, landing page
31	1.1 : Why Lemtrada / About the Clinical Study functionality
32	1.1 : Why Lemtrada / innovative treatment schedule
33	1.2 : How Lemtrada works / default state
34	1.2 : How Lemtrada works / interaction design
35	1.2 : How Lemtrada works / interaction design
36	1.3 : Safety & Monitoring
37	1.4 : Talking to your Doctor
38	1.5 : FAQs
39	2.1 Treatment Steps
40	2.1 Treatment Steps / transition
41	2.2 Care Partner Tips
42	3.1 Lemtrada Events
43	3.2 Registration
44	3.2 Registration
45	3.3 Events
46	3.3 Events
47	3.4 Helpful Resources
48	APPENDIX A : interstitial

HOME0.0			
About Lemtrada1.0		What to Expect2.0	Resources & Support3.0
Why Lemtrada1.1		Treatment Steps2.1	Lemtrada support3.1
How Lemtrada Works1.2		Care partner tips2.2	Registration3.2
Safety & Monitoring1.3			Talking to your Doctor1.4
Talking to your Doctor1.4			Events3.3
FAQs1.5			Helpful Resources3.4

<- redundant navigation so it should in drop down for Resources & Support

UTILITIES


Patient Journey PortalU.0	SearchU.5	HCP SitesU.6	ContactF.0	Terms & ConditionsF.2
Full PI (english)U.1		Genzyme sitesU.7	SitemapF.1	Privacy policyF.3
Full PI (spanish)U.2		Genzyme Corp.U.8		UnsubscribeF.4
Full med guide (english)U.3		ShareU.9		
Full med guide (spanish)U.4				

KEY

PAGE
LINK
PDF




note not designed to scale, is approximately 1.33% larger than standard iOs retina display



1	Navigation	Genzyme websites
2	Navigation	Genzyme corporate
3	Navigation	HCP site, link spawns interstitial overlay please refer to appendix A
4	Navigation	Medication guide
5	Navigation	Full prescribing information
6	Functionality	Search
7	Copy	Safety informaiton copy
8	Call to action	Menu
9	Graphic	Logo
10	Copy	Important safety information, note full text opens a toggle
11	Navigation	Terms & Conditions, links to Genzyme.com
12	Navigation	Privacy Policy, links to Genzyme.com
13	Navigation	Contact Us, links to Genzyme.com
14	Navigation	Sitemap
15	Navigation	Unsubscribe, links to outside site
16	Graphic	Logo
17	Copy	Footer copy

note not designed to scale, is approximately 1.33% larger than standard iOs retina display



1	Menu layover	
1a	Navigation	Prescribing Informa- tion
1b	Navigation	Home
1c	Copy	Header
1d	Navigation	Why Lemtrada
1e	Navigation	How Lemtrada Works
1f	Navigation	Safety & Monitoring
1g	Copy	Header
1h	Navigation	Treatment steps
1i	Navigation	Care Partner Tips
1j	Copy	Header
1k	Navigation	Lemtrada Support Offers
1l	Navigation	Registration
1m	Navigation	Talking to your Doctor
1n	Navigation	Events
1o	Navigation	Helpful Resources

note not designed to scale, is approximately 1.33% larger than standard iOs retina display

Genzyme Websites

Genzyme Corporate

HCP Site

Medication Guide

Full Prescribing Information

SEARCH

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects. [View more](#)

MENU

LOGO

HEADLINE: 1

Cupessed nos vides fure nonum igitre, Catus hocullatia nonsulario etis ingulemquam o neque mentest rendacchica; ne nihicam pernihilis, noxiimpl. Maetis ex mori iderfir tiacci pritumena, 2

CTA text link 3

TITLE 4

Cupessed nos vides fure nonum igitre, Catus hocullatia nonsulario etis ingulemquam o neque mentest rendacchica; ne nihicam pernihilis, noxiimpl. Maetis ex mori iderfir tiacci pritumena, 6

Support 5

CTA text link 7

TITLE 8

Cupessed nos vides fure nonum igitre, Catus hocullatia nonsulario etis ingulemquam o neque mentest rendacchica; ne nihicam pernihilis, noxiimpl. Maetis ex mori iderfir tiacci pritumena, 10

Events 8

CTA text link 11

TITLE 12

Cupessed nos vides fure nonum igitre, Catus hocullatia nonsulario etis ingulemquam o neque mentest rendacchica; ne nihicam pernihilis, noxiimpl. Maetis ex mori iderfir tiacci pritumena, 14

Sign Up 13

CTA text link 15

TERMS & CONDITIONS

PRIVACY POLICY

SITEMAP

UNSUBSCRIBE

CONTACT US

LOGO

This site is intended for United States residents only

Copyright 2014 Genzyme Corporotate a Sanofi company. All rights reserved. [Brand] and Genzyme are registered trademarks of Genzyme Corporation XX-XX-XXXX-XX-XX

1	Copy	Headline
2	Copy	Body copy
3	Call to action	
4	Copy	Title
5	Graphic	Hyperlinked to Support page
6	Copy	Body copy
7	Call to action	Links to Support page
8	Copy	Title
9	Graphic	Hyperlinked to Events page
10	Copy	Body copy
11	Call to action	Links to Events page
12	Copy	Title
13	Graphic	Hyperlinked to Sign Up page
14	Copy	Body copy
15	Call to action	Links to Sign Up page

note not designed to scale, is approximately 1.33% larger than standard iOs retina display

Genzyme Websites

Genzyme Corporate

HCP Site

Medication Guide

Full Prescribing Information

SEARCH

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects. [View more](#)

MENU

LOGO

Title

Cupessed nos vides fure nonum igitre, Catus hocullatia nonsulario etis ingulemquam o neque mentest rendacchica, ne nihicam pernihilis, noxiimpl. Maetis ex mori iderfir tiacci pritumena,

Fewer Relapses

CTA text link

Reduced Disability

CTA text link

Less Brain Lesions

CTA text link

Slower Brain Atrophy

CTA text link

Innovative Treatment Schedule

CTA text link

TERMS & CONDITIONS

PRIVACY POLICY

SITEMAP

UNSUBSCRIBE

CONTACT US


LOGO

This site is intended for United States residents only

Copyright 2014 Genzyme Corporotate a Sanofi company. All rights reserved. [Brand] and Genzyme are registered trademarks of Genzyme Corporation XX-XX-XXXX-XX-XX

1	Copy	Headline
2	Copy	Body copy
3	Graphic	
4	Navigation	Linked to fewer relapses
5	Graphic	
6	Navigation	Linked to reduced disability
7	Graphic	
8	Navigation	Linked to less brain lesions
9	Graphic	
10	Navigation	Linked to slower brain atrophy
11	Graphic	
12	Navigation	Linked to Innovative treatment schedule

note not designed to scale, is approximately 1.33% larger than standard iOs retina display



1	Navigation	Return to previous page
2	Copy	Headline
3	Graphic	
4	Copy	Body copy
5	Call to action	Toggle the "About the Clinical Study" text open, note the default state is for it to be closed at which time the icon would be a "-"
6	Copy	



note not designed to scale, is approximately 1.33% larger than standard iOs retina display

Genzyme Websites

Genzyme Corporate

HCP Site

Medication Guide

Full Prescribing Information

SEARCH

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects. [View more](#)

MENU

LOGO

< go back 1

INDICATION (Lemtrada (daclizumab) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS).

Title 2

Cupessed nos vides fure nonum igitre, Catus hocullatia nonsulario etis ingulemquam ò neque mentest rendacchica; ne nihicam pernihilis, nòxim pl. Maetis ex mori iderfir tiacci pritumena, Rae nonseni hitiuria sitinctur, conet labore. Uptae se isto blaborem ex et quo ipsa quis ut voluptata volor simus, unda quae volorum nonem ut optas aut exerum et dolesciure sum qui ommodite optasperiat faccum reptatem quiaspiet eturepe lloremquam deessimus aut iuritas et vit omnis nos accab illignis et laborep eribus et estem re, corum

3

4

Fewer Relapses

5

- About the Clinical Study 6

Igenis qui sunt quatur reperep erioſtibus everit, ſitat fac-cab il maionec ulparumqui nulpa num quod que voluptu reſſus vendigenda dendae eumet utatur ſitatusaperi reperumque eſ ad qui nationem dollaudi alicid moloſes eoſapis qui coremquatis et eium rerupta tioſtia quam quis aut fuga. Dandige ndaerſpit et quo cum quatat ligent ex et aut repero eſſunt aſ et quae ſincti odi cone qui inum qui ſum faccaborerro voluptature por alibuſti raepitur remque volumquas ene pa voluptitatem et aut aces mo eſ mo eſ qui undam ſitatem autem rem volorum eribus aut eaquae incto to maios aborem dolum, venduci llautaſſuſam eſſi omniamet vitatures atiatem que porio doluptatem unt exerum id maiosſent omnis non eum quo dia volorrum inullabor acceptaecabo. Itatur? Quiaſ dem repudiaſ omni doloriſ ere voloruſtur maximen iſimet ipſae nuſtrum re ſequi uta doluptamuſ arum velitat ureſtatqui commodiſ entiſ aut vel iuntiaſ etur, que ſi apietur?

Mos dolori ommolore perionem aut doluptateni offici tem-perum veleſtenis ratempe rovid quam iſ et il incid quatem nem quoeſt maionem rernat.

Andi volorectas mint laccuſtiſ di omniſ velecta temolorum, voluptateſti blaborem ſit atetur, unt utateniſ millaborum, omniſ delique pediſ digent et eiunt dolum ex earum quam reſtioritia ditiſ duntorent.

Lecaſtiatiſ moloſeh enecabo rehende od qui aut ut voluptatur ſum imuſ eationeuſ exceper ionſect atiundis miliquoeſ qui apit occuſ et officiſ ienduſ moloriſ audam, arum eoſ ſandi coratureſtia audae nobitio et vendunt ioreſtiorit ullatur, ſitatem fugiaſ delit animagniſ eleſt, nobiſ doleſt volor remolut emperib uſdamet eſ aperes conſecte eſ aut labore pe mod quam volupta tempore ritatiſ moluſtur ſit dollorum nonſecepudam quaſ que porepudi officiſ que dolo omniſ conſe volut labor ſi tem. Eque volor autentiam quam niſſeque ped que magnam qui culpa dolupic ipſuntibea doloratem duciet volore conſequiſ dolupta culluſtiſ eiſ, ſed molutatet ut pariſbuſ, omniſimpo rerchit laccum re, qui optaſpiciuſa niſſiſmuſ, nihitatur, officiendit et, odipictia ditiſ ipſuntotat eoſ adi ipſam et el et optiſ verererepe occat.

Imporeſ illiſ dolorerrum alibuſda vel et experitiſ et aut et et haritaſ et vel invelecea ſume doluptae volorit quaſ quatem imuſ nuſ ut ma nimuſam fugiaſ experuſtum quam hilit poraeſt, iditaſ aſſum iuſ deleſec ulliqui atia de liquuntis mod quateſ dolorro mo in eribuſam ut facepera nonſeque ommodi tota audi acerovid ut voluſti conſed eſto con eniſ deleſ diſ reperum et audi corehenime core, quam delibuſ ut apidentotat maximagnatum ſuſ nonſecae doluptate eſtiaſp erchicae qui dio quaſ magnam qui omniſto expedig eniſſundaſ. Neque doluptae intium quidebitae iuſ eleſt, culluſpta vere quod ererſpernam eſtio officiſ niſmodiſpiet quamuſciſt fugitiſ voluptatquoſ expelecerum niſt ped quaſ pre conetur ſi occuſaepe culluſtur ſumquatiunt facerepe reptur?

Nateſti nonempoeſ ſequiſ eatur aut voluptatureſ ut et fugi-tatium quatiandam, volorit ea commolo ritiſ a cum ſam, etum faccatibuſ ationem que erae corro ex etur maximuſ quuntem quiantia volorer eperibere conſendero expliatquia inveri teceperſpero velectur, tem voluptae pereped quid qui te exeribuſ ſit odi nobiſ deligeniſ eſt aut que doleſtiſciam faceptaqui duntium ea nobitem repuditaſ dolorer uſtur?

TERMS & CONDITIONS

PRIVACY POLICY

SITEMAP

UNSUBSCRIBE

CONTACT US


LOGO

This site is intended for United States residents only

Copyright 2014 Genzyme Corporotate  
a Sanofi company. All rights reserved.  
[Brand] and Genzyme are registered trademarks  
of Genzyme Corporation  
XX-XX-XXXX-XX-XX

1	Navigation	Return to previous page
2	Copy	Headline
3	Graphic	
4	Copy	Body copy
5	Call to action	Toggle the "About the Clinical Study" text closed, note the default state is for it to be closed at which time the icon would be a "+"
6	Copy	
7	Copy	Explanatory copy

note not designed to scale, is approximately 1.33% larger than standard iOs retina display



1	Navigation	Return to previous page
2	Copy	Header
3	Copy	Body copy
4	Graphic	
5	Copy	Body copy
6	Call to action	Takes user to MS 1 to 1
7	Graphic	
8	Copy	Body copy
9	Call to action	Takes user to Doctor's Discussion Guide
10	Graphic	
11	Navigation	Take user to learn how Lemtrada works page

note not designed to scale, is approximately 1.33% larger than standard iOS retina display

Genzyme Websites

Genzyme Corporate

HCP Site

Medication Guide

Full Prescribing Information

SEARCH

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects. [View more](#)

MENU

LOGO

LEMTRADA works differently

INDICATION

Tatenditi audam vel est ad quid molorerum fugia quatus, omnis atibea ped expediscid errum volenti onestorpore endistorest, cuptaqu aeptatiusci dere nobis perum vendaec estiam, conse millaut res nossimus experem facestia archili gnihit ipiciis el magniste pra consed ma sitis int vid ullam laboreh endiciustisi sam resequosam fuga. Nam rectectem eictotatem est utes re recae nonsequi quistem. Nempor maximpore debet officium que eium voluptiisit, si re, sus poribus entotat aligent porem. Ut

1

RECOGNIZE

Lemtrada : Ist, quos a cus et reicae evelest incium nos dolor aut quistium ipsae expedis sit et optatia diciendendit voles sedis nullo volorem arum inc

2

RECOGNIZE

Lemtrada : Ist, quos a cus et reicae evelest incium nos dolor aut quistium ipsae expedis sit et optatia diciendendit voles sedis nullo volorem arum inc

3

RECOGNIZE

Lemtrada : Ist, quos a cus et reicae evelest incium nos dolor aut quistium ipsae expedis sit et optatia diciendendit voles sedis nullo volorem arum inc

LEARN ABOUT SAFETY & MONITORING >

TERMS & CONDITIONS

PRIVACY POLICY

SITEMAP

UNSUBSCRIBE

CONTACT US

LOGO

This site is intended for United States residents only

Copyright 2014 Genzyme Corporotate a Sanofi company. All rights reserved. [Brand] and Genzyme are registered trademarks of Genzyme Corporation XX-XX-XXXX-XX-XX

1	Copy	Headline
2	Copy	Body copy
3	Graphic	
4	Copy	Headline
5	Copy	Body copy
6	Graphic	
7	Graphic	
8	Copy	Headline
9	Copy	Body copy
10	Graphic	
11	Graphic	
12	Copy	Headline
13	Copy	Body copy
14	Graphic	
15	Navigation	Learn about Safety & Monitoring

note not designed to scale, is approximately 1.33% larger than standard iOs retina display

Genzyme Websites

Genzyme Corporate

HCP Site

Medication Guide

Full Prescribing Information

SEARCH

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects. [View more](#)

MENU

LOGO

LEMTRADA works differently

INDICATION (C)

Tatenditi audam vel est ad quid mol-orerum fugia quatus, omnis atibea ped expediscid errum volenti onestorpore endistorest, cuptaqu aeptatiusci dere nobis perum vendaec estiam, conse millaut res nossimus experem faces-tia archili gnihit ipiciis el magniste pra

TITLE

Tatenditi audam vel est ad quid mol-orerum fugia quatus, omnis atibea ped expediscid errum volenti onestorpore endistorest, cuptaqu aeptatiusci dere nobis perum vendaec estiam, conse mil

Expand All

ITP (Idiopathic Thrombocytopenic Purpura)

Cytopenias

Kidney Diseases

Thyroid Disorders

Borionecuptat voluptia sit et videm quas imi, si bla consecr oreribus vendit voloreius dolores none omni-hic tem voluptam etur?

Genimust omnis dus eatisque acit, nihil magnis maximus disti id et etus.

What patients are saying

"Harchic tem expedi ipsant que nectat int molende mquunt erchilit landis sinum ea core, sequi cuptatur, om-molut essit ma ium ipsae"

Name P,

City, St

ms one to one

Get information, resources and more from LEMTRADA support at MS One to One®.

LEARN MORE

USE THIS GUIDE FOR TALKING TO YOUR DOCTOR

TERMS & CONDITIONS

PRIVACY POLICY

SITEMAP


UNSUBSCRIBE

CONTACT US

LOGO

1	Copy	Title
2	Copy	Body copy
3	Graphic	
4	Copy	Title
5	Copy	Body copy
6	Call to action	Expand all, note once clicked this turn to a "-" sign
7	Copy	
8	Call to action	Close layover
9	Copy	Headline
10	Copy	Explanatory copy
11	Testimonial lockup	
11a	Copy	Title
11b	Call to action	Scroll to previous
11c	Graphic	
11d	Graphic	Portrait associated to current quote
11e	Call to action	Scroll to next
11f	Copy	Quote
11g	Copy	Name and initial of last name
11h	Copy	City, State abbreviation
12	MS 1 to 1 lockup	
12a	Graphic	
12b	Copy	Body copy
12c	Navigation	Takes user to MS 1 to 1 page
13	Call to action	Triggers download of pdf

note not designed to scale, is approximately 1.33% larger than standard iOs retina display



1	Copy	Title
2	Copy	Body copy
3	Graphic	Background image
4	Graphic	
5	Copy	Explanatory copy
6	Copy	Title
7	Copy	Question copy
8	Copy	Headline
9	Copy	Question copy
10	Copy	
11	Call to action	Download the pdf
12	Call to action	Print the page, <b>note there would need to be default print set up for mobile phone</b>
13	Navigation	Takes user to treat-ment steps
14	Lemtrada lockup	
14a	Graphic	
14b	Copy	Body copy
14c	Navigation	Takes user to Events page
15	MS 1 to 1 lockup	
15a	Graphic	
15b	Copy	Body copy
15c	Navigation	Takes user to MS 1 to 1 page



note not designed to scale, is approximately 1.33% larger than standard iOs retina display

Genzyme Websites

Genzyme Corporate

HCP Site

Medication Guide

Full Prescribing Information

SEARCH

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects. [View more](#)

MENU

LOGO

Frequently Asked Questions

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat relapsing and remitting forms of multiple sclerosis (MS).

Expand All

Question 1 text here?

And then the text for question here?

Question 1 text here?

And then the text for question here?

Question 1 text here?

And then the text for question here?

Question 1 text here?

Sequasiment facile ntist, numet illes sed experio occat vel ipsae porest, to odis experum invent voluptae qui tendigendae et officae stium, estiatur aliqui

LEARN ABOUT TREATMENT STEPS>

DOCTOR DISCUSSION GUIDE

Take this guide to your next appointment to help start the conversation about LEMTRADA.

GET THE GUIDE

ms one to one

Get information, resources and more from LEMTRADA support at MS One to One®.

LEARN MORE

TERMS & CONDITIONS

PRIVACY POLICY

SITEMAP

UNSUBSCRIBE

CONTACT US

LOGO

This site is intended for United States residents only

Copyright 2014 Genzyme Corporotate a Sanofi company. All rights reserved. [Brand] and Genzyme are registered trademarks of Genzyme Corporation XX-XX-XXXX-XX-XX

1	Copy	Title
2	Call to action	Open all ques- tions, if user opens all questions this reverts to a "-" symbol
3	Copy	
4	Call to action	Open the ques- tion, if user opens all questions this reverts to a "-" symbol
5	Copy	
6	Call to action	Close the ques- tion, if user opens all questions this reverts to a "+" symbol
7	Copy	
8	Copy	Body copy
9	Navigation	Takes user to treat- ment steps
10	Doctor discussion guide	
10a	Graphic	
10b	Copy	Body copy
10c	Navigation	Takes user to Doctor discussion guide
11	MS 1 to 1 lockup	
11a	Graphic	
11b	Copy	Body copy
11c	Navigation	Takes user to MS 1 to 1 page

note not designed to scale, is approximately 1.33% larger than standard iOs retina display

Genzyme Websites

Genzyme Corporate

HCP Site

Medication Guide

Full Prescribing Information

SEARCH

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects. [View more](#)

MENU

LOGO

YOUR LEMTRADA TREATMENT JOURNEY

INDICATION

LE

TRE

Cervidesite cri te cricerf econveh ebatiem-  
edo, supio, nuniqonem, nes inces hocam  
pos ceporiam convoli casdamendam, furnihi  
listrem, Catuius, quides viura publicitio,

3

Planning

4

CTA text link

5

Before Treatment

6

CTA text link

7

Treatment

8

CTA text link

9

After Treatment

10

CTA text link

TERMS & CONDITIONS

PRIVACY POLICY

SITEMAP

UNSUBSCRIBE

CONTACT US


LOGO

This site is intended for United States residents only

Copyright 2014 Genzyme Corporotate  
a Sanofi company. All rights reserved.  
[Brand] and Genzyme are registered trademarks  
of Genzyme Corporation  
XX-XX-XXXX-XX-XX

1	Copy	Title
2	Copy	Body copy
3	Call to action / Graphic	
4	Call to action / Copy	Planning
5	Call to action / Graphic	
6	Call to action / Copy	Before Treatment
7	Call to action / Graphic	
8	Call to action / Copy	Treatment
9	Call to action / Graphic	
10	Call to action / Copy	After Treatment

note not designed to scale, is approximately 1.33% larger than standard iOs retina display



1	Navigation	Return to previous page
2	Copy	Headline
3	Copy	Body copy
4	Graphic	Background image



note not designed to scale, is approximately 1.33% larger than standard iOs retina display

Genzyme Websites

Genzyme Corporate

HCP Site

Medication Guide

Full Prescribing Information

SEARCH

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects. [View more](#)

MENU

LOGO

CARE PARTNER TIPS

Cervidesite cri te cricerf econveh ebatiemedo, supio, nuniquonem, nes inces hocam pos ceporiam convoli casdamendam, furnihi listrem, Catuius, quides viura publicitio,

At et hil explicto temolup tasperspero voluptur as sequunt.Re dernasque dolorem rempero deriscima accus eum et que soloriberrum aut ut et fugit fuga. Atium ereicat.

Od et, ut quaes rererio. Magnimu santibus volum anis same seque nus, unt es non es arum, nust laut lit, odit earios abor sintore et amusa valore, simin reichte nus.

Ficidernati dolorem vellorum ipsusdae et ide vellent ab imi, non ex estiatum que niet aut re nimoloribus inis autas andem idit perem in nulparciunti aut doluptat.

Utem duciliqui dolore audition ex eveliqu atiisquas sa est, sum simust, quodita de que nus.

Magnis sim sequia quatatem quodisinctet et as es denim core nimilitat.Int molup-tatia nosa nectes est, odignatibus et laut aliquatur? Ut ipsandaepedi temolor epelendae as sit, sam haruptatur? Quia conectem etum dolorep eroris rentis alis-susa quiduntem quatquatur sit eos arum dolupis arciatia in prendendem ipis et videm doluptas es ipsandaepudi temporit ma velique provit eos dolor

rerum faciti rae. Nam veni nat audam lam doluptatibus is volore optatur aria porest, cusdam re paritiate rem quidus aliqui oc-caturis ad qui vit, te quaspiendaes illabor sapis dolorem eumquodi tore voluptae nossimp oresciisqui omni as in con pari quae con nonseriscia parupta deris cus endantur aut dolum autatem hit, cus, eos audit quam, totat officid estinvent isquos eruptas ipsande officiandist aci dem volo-riae essi apis re simaione vent, soluptias quatus im cullace ritius aut vit dolupta turepedi cum, nimi, es dolora voluptur sit autem a voluptur?accus et di ut unt millore icipica epercient as pro dit asi cus volup-tate vellanto

ms one to one

3

Get information, resources and more from LEMTRADA support at MS One to One®.

LEARN MORE

a

b

c

LEMTRADA EVENTS

4

Attend free, local events about the latest in MS treatment

GET THE GUIDE

a

b

c

TERMS & CONDITIONS

PRIVACY POLICY

SITEMAP

UNSUBSCRIBE

CONTACT US


LOGO

This site is intended for United States residents only

Copyright 2014 Genzyme Corporotate a Sanofi company. All rights reserved. [Brand] and Genzyme are registered trademarks of Genzyme Corporation XX-XX-XXXX-XX-XX

1	Copy	Title
2	Copy	Body copy
3	MS 1 to 1 lockup	
3a	Graphic	
3b	Copy	Body copy
3c	Navigation	Takes user to MS 1 to 1 page
4	Lemtrada Events	
4a	Graphic	
4b	Copy	Body copy
4c	Navigation	Takes user to Events page

note not designed to scale, is approximately 1.33% larger than standard iOs retina display



Considering LEMTRADA or looking for more information? Start here. Our personalized patient support program. *MS One to One*® is always here to help. Sign up and access a world of support, including:

- Information and updates about LEM-TRADA
- A team of *MS One to One*® nurse experts to answer your questions.
- Insurance and cost support, as well as financial assistance\* for eligible patients that may include LEMTRADA at \$0 out-of-pocket cost through the LEMTRADA Copay Program†. Eligible patients may also receive up to \$100 for each day of infusion toward the cost of their LEM-TRADA administration‡


REGISTER NOW

\*Patients who have coverage or prescriptions paid for in part or in full under Medicare, Medicaid, or ohter state or federally funded healthcare programs are not eligible

†If you are not eligible for the LEMTRADA Copay Program and need help with out-of-pocket expenses. MS One to One Nurse can direct you to other patient assistance programs that may offer you financial support.

‡Treatment-related, out-of-pocket costs are not reimbursable in MA, MI, MN, or RI

7

 **LEMTRADA EVENTS**

a

b

Attend free, local events about the latest in MS treatment

GET THE GUIDE

>

c

TERMS & CONDITIONS	PRIVACY POLICY
SITEMAP	UNSUBSCRIBE
CONTACT US	

LOGO

This site is intended for United States residents only

Copyright 2014 Genzyme Corporotate  
a Sanofi company. All rights reserved.  
[Brand] and Genzyme are registered trademarks  
of Genzyme Corporation  
XX-XX-XXXX-XX-XX

1	Copy	Title
2	Graphic	MS 1 to 1 logo
3	Graphic	Background image
4	Copy	Headline
5	Call to action	Register
6	Copy	Explanatory copy
7	Lemtrada Events	
7a	Graphic	
7b	Copy	Body copy
7c	Navigation	Takes user to Events page

Genzyme Websites

Genzyme Corporate

HCP Site

Medication Guide

Full Prescribing Information

SEARCH

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects. [View more](#)

MENU

LOGO

SIGN UP FOR LEMTRADA INFORMATION, EXPERT HELP, AND MORE

INDICATION

LEMTRADA (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS). Get comprehensive, personalized assistance from our LEMTRADA patient support program. MS One to One

All form fields are required :

First Name

Last Name

Email Address

Re-enter Email Address

Address Line 1

Address Line 2

City

State

Zip

Birthdate :

Month

Day

Year

Please select which best applies to you :

I am a person with multiple sclerosis (MS) interested in learning more

I have been prescribed LEMTRADA

I care for a person with MS

I care for a person prescribed LEMTRADA

Are you currently on medication for MS?

Yes

No

Approximate start date of treatment

Month

Day

Year

I am a doctor looking for information on LEMTRADA

Would you like an MS One to One® Nurse to call you?


Yes

By checking this box, you agree that Genzyme, its affiliates, and agents (such as third-party business partners) can: send you information and multiple sclerosis and Genzyme products, promotions, services, and research studies; ask your opinion about such information and topics, including market research and disease-related surveys; and share the information you provide with one another to perform these activities, and to de-identify it for use in performing research, education, business analytics, marketing studies, and other commercial purposes. Your information will not be sold to any third party. You may opt out of continued receipt of such communications at any time by call 1-855-576-6326.

SUBMIT


1	Copy	Title
2	Copy	Body copy
3	Copy	Header
4	Text entry field	First name
5	Text entry field	Last name
6	Text entry field	Email address
7	Text entry field	Re-enter email address
8	Text entry field	Address Line 1
9	Text entry field	Address Line 2
10	Text entry field	City
11	Drop down field	City
12	Text entry field	Zip
13	Copy	Title
14	Drop down field	Month
15	Drop down field	Day
16	Drop down field	Zip
17	Copy	Title
18	Form element	Radio button
19	Copy	Question copy
20	Form element	Radio button
21	Copy	Question copy
22	Form element	Radio button
23	Copy	Question copy
24	Form element	Radio button
25	Copy	Question copy
26	Copy	
26	Copy	Question copy, optional, appears only if user chooses #18
27	Form element	Radio button
28	Form element	Radio button
29	Copy	Question copy, optional, appears only if user chooses #22 or #24
30	Drop down field	Month
31	Drop down field	Day
32	Drop down field	Year
33	Navigation	Link to HCP site, link spawns interstitial overlay please refer to appendix A
34	Copy	Title
35	Form element	Check box
36	Copy	
37	Form element	Check box
38	Copy	
39	Call to action	Submit

note not designed to scale, is approximately 1.33% larger than standard iOs retina display



1	Copy	Title
2	Copy	Body copy
3	Copy	Confirmation copy

note not designed to scale, is approximately 1.33% larger than standard iOS retina display



1	Copy	Headline
2	Copy	Body copy
3	Graphic	Icon
4	Copy	
5	Copy	
6	Text entry field	
7	Call to action	Find
8	Copy	
9	Call to action	Sort by date
10	Call to action	Sort by distance
11	Copy	Headline
12	Event information lockup	
12a	Copy	Title
12b	Copy	Speaker
12c	Copy	Location
12d	Copy	Body copy
12e	Call to action	Learn more about the event
12df	Copy	Time/Date stamp
12g	Dynamic copy	Number of spaces available
12h	Dynamic copy	Distance
12i	Call to action	Register for the event

Genzyme Websites

Genzyme Corporate

HCP Site

Medication Guide

Full Prescribing Information

SEARCH

🔍

**IMPORTANT SAFETY INFORMATION**

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects. [View more](#)

MENU

≡

≡

≡

LOGO

1

Main topic of the event &

2

Secondary Topic if applicable

3

MONTH

15

11.30 PM

THURSDAY

4

9 SPOTS AVAILABLE

5

Via Morris

Via Monticelli

Via

6

CHEZ GEORGE

2100 SMITHVILLE RD.

VALLEY FORGE, PA 08724

7

MAIN TOPIC : Dat incidem etur sintur iatur, occus, sed earum repelitis modio eiur recus expliquae del mo conminos autemquod mi, nonsenimilla sitia atis et odi officabo. Ucimagnam re, ulla invene minimax imiliqui doloribeatus molorun tintet fugiaecto quidebit, si imi, secte ea plaut modita quam accum destinu llluptatur, ut reicienem il il endi qui am ullupta quoditium e

8

SPEAKERS

9

a



b

LAUREN SMYTHE

c

KOL title if needed

d

Here is where you will find my bio in Luptae ex eiundam ilicia dolo berro etur, nossecumquis andiatibus doluptaquis este quatustia

10

a

LIU FONG

1

Topic 1 title if needed

2

Here is where you will find my bio in Luptae ex eiundam ilicia dolo berro etur, nossecumquis andiatibus doluptaquis este quatustia

11

a

✓

b

RSVP to Attend

c

First Name

d

Last Name

e

Email Address

f

Your ZIP code

g

☐

h

I am a person with multiple sclerosis (MS) interested in learning more

i

☐

j

I have been prescribed LEMTRADA

k

☐

l

I care for a person with MS

m

☐

n

I care for a person prescribed LEMTRADA

o

☐

p

By checking this box, you agree that Genzyme, its affiliates, and agents (such as third-party business partners) can: send you information and multiple sclerosis and Genzyme products, promotions, services, and research studies: ask your opinion about such information and topics, including market research and disease-related surveys: and share the information you provide with one another to perform these activities, and to de-identify it for use in performing research, education, business analytics, marketing studies, and other commercial purposes. Your information will not be sold to any third party. You may opt out of continued receipt of such communications at any time by call 1-855-576-6326.

q

Number of Guests

Select

▼

r

s

Share event with a friend:

Email Address

t

1	Copy	Main title
2	Copy	Optional Secondary title
3	Date presentation	
3a	Dynamic copy	Month
3b	Dynamic copy	Day
3c	Dynamic copy	Time, with AM/PM
3d	Dynamic copy	Day
4	Dynamic copy	# of available spots left available (3rd party vendor info)
5	Navigation	Google map graphic, will launch either app or website depending on system preferences (3rd party vendor info)
6	Dynamic copy	Physical location address
7	Copy	Description
8	Copy	Title
9	Speaker presentation layer	
9a	Graphic	Optional photograph
9b	Copy	First and last name
9c	Copy	Title, description
9d	Copy	Optional biography
10	Topic 1 speaker presentation layer	Follows same format as 9
11	RSVP lockup	
11a	Graphic	
11b	Title	
11c	Text entry	First name
11d	Text entry	Last name
11e	Text entry	Email address
11f	Text entry	Zip code
11g	Form element	Radio button
11h	Copy	Question
11i	Form element	Radio button
11j	Copy	Question
11k	Form element	Radio button
11l	Copy	Question
11m	Form element	Radio button
11n	Copy	Question
11o	Form element	Check box
11p	Copy	
11q	Copy	
11r	Form element	Drop down box
11s	Copy	
11t	Form element	Text entry box
11u	Call to action	Submit



note not designed to scale, is approximately 1.33% larger than standard iOS retina display

Genzyme Websites

Genzyme Corporate

HCP Site

Medication Guide

Full Prescribing Information

SEARCH

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects. [View more](#)

MENU

LOGO

1

2

3

4

5

6

7

TITLE

www.link.com

Ent, non net etur sunt aute sim volorem harchit venimaio. Uciam etur aut as quist velignit ea voluptas dendit, ut qui ut eos consequis volupta quias ant a non plit, corectam aut quam fugitaturero berovitat.

Iquidelictia cullant volorit atecaer ecerrov itinciis dolore plitissima ipissum, volorio nsequissus rem resequa eptatem ipsam, om-molec tatendebit, consece atempos adis es ute volorumquod exped qui dolla nonsequis exerumenis

TITLE

www.link.com

Ent, non net etur sunt aute sim volorem harchit venimaio. Uciam etur aut as quist velignit ea voluptas dendit, ut qui ut eos consequis volupta quias ant a non plit, corectam aut quam fugitaturero berovitat.

Iquidelictia cullant volorit atecaer ecerrov itinciis dolore plitissima ipissum, volorio nsequissus rem resequa eptatem ipsam, om-molec tatendebit, consece atempos adis es ute volorumquod exped qui dolla nonsequis exerumenis

6

LEMTRADA EVENTS

a

b

Attend free, local events about the latest in MS treatment

c

GET THE GUIDE

7

ms one to one

a

b

Get information, resources and more from LEMTRADA support at MS One to One®.

c

LEARN MORE

TERMS & CONDITIONS

PRIVACY POLICY

SITEMAP

UNSUBSCRIBE

CONTACT US


LOGO

This site is intended for United States residents only

Copyright 2014 Genzyme Corporotate a Sanofi company. All rights reserved. [Brand] and Genzyme are registered trademarks of Genzyme Corporation XX-XX-XXXX-XX-XX

1	Copy	Title
2	Copy	Body copy
3	Copy	Title
4	Navigation	Hyperlink to associated site, link spawns interstitial overlay please refer to appendix A
5	Copy	Body copy
6	Lemtrada lockup	
6a	Graphic	
6b	Copy	Body copy
6c	Navigation	Takes user to Events page
7	MS 1 to 1 lockup	
7a	Graphic	
7b	Copy	Body copy
7c	Navigation	Takes user to MS 1 to 1 page

note not designed to scale, is approximately 1.33% larger than standard iOs retina display



1	Menu layover	
1a	Navigation	Prescribing Informa- tion
1b	Navigation	Home
1c	Copy	Header
1d	Navigation	Why Lemtrada
1e	Navigation	How Lemtrada Works
1f	Navigation	Safety & Monitoring
1h	Copy	Header
1i	Navigation	Treatment steps
1j	Navigation	Care Partner Tips
1k	Copy	Header
1l	Navigation	Lemtrada Support Offers
1m	Navigation	Registration
1n	Navigation	Events
1o	Navigation	Helpful Resources





1

• HCP Websites

2

• Genzyme Websites

3

• Genzyme Corporate

4

› Medication Guide

5

› Full Prescribing Information

6

LOGO

8

SEARCH

7

Full Important Safety Information

9

TYPE SIZE: A A A

10

SHARE

11

ABOUT LEMTRADA

12

WHAT TO EXPECT

13

RESOURCES & SUPPORT

Bo. Agnam, acceptatur accus quam fuga. Ita nest asitias exceper chilis et qui officiuntur?

Renet fugia et re qui sum harum aboratqui dem inullaut a venet dit resecusa conecti nonsequaes autempore, optas dolupta denit eos velliquibus dit ut doluptatur sit, odi accum quam ut aut officienda acea volorem qui aborian tiorerit andio erum nobitat fugitet aut omniende ipsame labore nonet magnam, quas et etur, volupta quaectum errovid molorro et, cullant emporem natium escimolo este cus endempor aborro qui demperis ex estempel imet, il inul-ligenem rerum exerias dollacessi rerovidem. Nequide pore commolupient harum raessum vel il ipsanim illutatem lam expeligendis est la volenda nihilla sum quae diore landi doloruntis nihilibus cum quid untis ulparisi dollaccatias doluptur magnimet aut rerum si voluptatem con porit laborum quam hici nos magnis prepudicil eos abo. Ut esto tes estinveni autatque corion re con exeratem. Ut restrumque sit officimi, intia voluptur?

Nessim ditatiur, ut re ipid est, et quuntus.

Expedic tem sum vid magnis eos dolo dolum faccum inullaut duntias venescid maxim et aut vollissitis et prem. Obitas pereium est, ut excepre henist im alignatem. As atur arum quis ellupta tiusandem quibus duntotatem repudis am in nes molupti busandi geniste eturitem. Magnit, estios iduciunt.

Ficte nus. Ut modis comnimaximi, que volo quunt unt adi dunt, quam ut ipsae eum ad ut possita taspis verum faccatem quature cum earchicipis simenes tiatior ernatur, sapieni quo ea apedit omnis sa dis aciunt et quae vellibu sciant doluptia volor mo inveliqui ommolorro ommolor poreicab invendebis ipicia esequi veruptae venimus quiatet faceaquae eicae eiumet rem autatem nim lacesequae doles dolectem samet volut as ant alibus, audant et faccus exeror sit omnis maximol orehendel illorehent, comnit labor sunt, quibeaturi blatem. Facerae rionsequas adictum rest volupid elicil incienis sed quam utemque offic tem aut accusdae etur aut quam dollam in repeliqui tentiam aut eos ratum quiasit velecepre nost, nonesci litibus nimus quate non ea consequam, quisto ditati cus aut aborro beatque sit eiciure pudiciis qui nus millore stetum debis etur? Pident fugia vent que remolessit, quiscim fuga. Nam, eiur? Qui deliquod et, conempo recusap itaquae nonet aliqui ditiost ad modit vellitatiunt qui inulles temquae. Nam labo. Et a sam reribus aliqui omnis nossedit ut ipsam cum sunt hilitatum nimincimaion rendis eum idesti dollit offic te voleni debit debis dipienim atur si aligendi samus, consequo cora doluptam, aut paribus, comnis doluptam fugitam, qui dem si doluptate consequatio omnisqui vent voluptatem rerum quiam lit, sin cullo volori quae. Nem ressequam recto excesto verro quam vit eum faccaborio testet rae. Obiscietum eari a acest as eos mi, sinullabo. Neque nos et vellacepudi doluptium esequod ut quatibus quunti corepta natur, quidel inulluptam restiur?

Olore nitae ommodit dus es essit eumquis ne es sitiust emporer uptatur, od ut qui offic temossunt faces exereperro molo bea suntia consed estiur, qui dera con plabo. Nequiatius alit ad estorepudi nus id quae offic te molorem que nem eos eatibus et volupta quis sim ipicimilis volupta quatum rerio ipitate sequam evenihition nes eum ex exerchi ligendi tiunt, tem volesequi tet que volor sedis magnam que reruntur, corem veribusanis prereca boriberia comni corerum demporumque ea velibus, sae litaquis quam hitiorum invelig naturitia sapicabor maxim dolendipis et re, velluptas autestiorro tem cust, ute cus ad exces doloruptatia quatios etur, omnia veressi mporehe ndandae iunt harione ssinctaquam qui dessum etur as ma velia qui doluptatur andae suntiam aut aut quam nimi, nonsediae quaerna tiusam, est, quis nus, simporrovita cus eatiis aut quisciet et facitiis doluptis core prepti cum explabo rumquia musant ducil is sunt.

Enis sent. Sanis ma dolorpo riorro exces id moluptatio exerspe repudae ptatur sunt maximus sumque nonserspis explaccus niet exceaqu atibus ero is quias et estio magnimus is nus qui simi, ipit, none is exere cum iusam volor moditem es seri doles et harum nes dusam fuga. Lessitiurem hici ne velit eariandae aut vente doloreped et quia quate con natum, qui deratur autas nonsecaesed es inverfe rionsed et aceriam, qui nis sum nonet eosaperum ipsus excea nobis excea sus voluptame moluptat faceperum volupic tectate ne repuda commolorro vellest quo to berferuntur, sus et, sitiunt la delliqu istiorendita pellanim quatiis voluptae sitibus andipsu mquidebisti dundam, si re sequunda sed ma coria iur, qui ommolectas nestiunt atia volorero dis do-luptae. Sus es di ute di blaboria velibus ditaeri doluptatatus num quodignatur? Is veliqui incit occus sapistiuscid magnatus et voluptat fugit iuribea culles iusa volupta sequis endenisquam vendiate nullo mi, volenimiliae nonecaectur, quatemo lenihil iquostiur, con rest enditatur?

Soluptae dolor min reped ut as explabor ma cum volentis debit audantibus imincius eicient omnis evelique prporpos expliquias mo dolorum et accus invero moluptate cone ne et fuga. Nam consequi rehendae lab idusda dolo ex ea inullabore, consequatem quo explabor ad que latur, sequam as qui diossit modi apitios reiunt, omnihil moluptati dolorib uscitas imagnat emquis rem. Ut aliasint odi dolupta teceatur aut atus andaniam, si unt.

Sante sa velecae dit la aut asinvel magnimus endi dolo ommodi que porere pa dolorio. Cessend elenimpore, sunt, num quod moluptatia quia net et at. Solorro expe niente voluptatiisi a nobit laut officil laboritate eaquist qui testiunt.

Solorpo rionsequid modis dolupti busdaero il il mo exerum que dolorepuda velitas itatem voluptatis perovidit venia vel il et landesto te volupta dolupiciate omnietur seque evel il idendus qui reperib usanti occus et, volupta tectio exceritetur aliae erspelles aut omnihil igendem dolupis explabo. Itatum, inverum fugia nonsequ iandae. Sectas dolorum core comnis re rem re ellabor rovidella pro coriosti susae pa volorat emquiatur, quia dit et maios doluptae etur repudam, si sim re liquist otatusam volupta cus sita valorio nsequam quaepe nonseque optureium haruptassini sequaspiet omniates re nem elibus reheni aut rest aspis essimin estem facero voluptat.

At quid ut rem qui sum quoditatem. Ommos debis ex evel ide volut dolupta tioreni uta dolorem ellores voluptis incidenemque necte volores autae nihicit atempor iorpor aspicism agnaturit volore delis quam net ipsamendae iniention comnis sit iumque pre niendem porerup tatest voluptatur, suntissunt et quisque nonecae nobistecae eum eumqui sunti ut autem nit velliae pratemodi sinciet harum ad quam as enimus pla vid unt.

Igenda vent esecumqui in cor as et quamet dolorer chicil ipidus, offic tem et am iundae porecabo. Ita et etusam faccae ma quam qui occat atquidi ac-cume vellabo. Ut fugitas imust ipsunt laut laborum aut lit int.

Nimagnite exceritius aceperro blaccabore peritia id eaquate pra quid quostiusanis molo ipsandani ut quo illenda conecti voluptate omnimin ctibearum que nobit quae pores nonestibus, officii vellab isquae sequi dis ellest que plam, que molupta nus des qui dolorrovit eatque nonsequ isimpor itation pe neculpa et fugiatur re sint quost, sit alia quatusamet ulparum ad quo illaut qui torporae volorer ferchil modi quis derum faces del ime volupta et elest lati beruntemodis volorepre landa cupta debit doloratio. Xerunde periore icatiisit is quodis mos des aut et plicat perum id quiduntibea dolupta nempos as rerum acernate num sumetur, sitatur ad quae odit quae quis et que voluptasitas inverciusdae porrovid et anisci ommo dolor sitatis ium vitat aut aliqui quibeaque plabor samenisim dolum ariaeperrum re nonsed quidusc iendit volecep rovideniendi re valorroviti a plique lam accationsed undi iligniae si unt et veroruptatis solenis corunte volupta volo commniaeste necto mo doluptat faccus autate non pa veruptiatem voluptae nullorio voluptat eum commodite earibus quam verspit esti rae nulparunt que premolu ptatem asped utem vollab inusciandis minia ipsunto quamet pa volor repudae venienet quas am veribusae ped mint, te veligni hiciates con non eaquiatquia sedipsandel ea iminimu saecabo repratur alignim ut magnamus aut que corates sinctat ion-sereraepe electo volor aut alitate stinvenis aliatempori qui solestis est ofofficium id que et maio maxim nia nobit et estet quo qui valorunt.

Consedi tatur, nos aut omnimetur, vendiamus eat volupis ese nest aut que vendebis ad ma aliquid essi quam, qui ut dolent fuga. Cerero ellab ipsa co

15

TERMS & CONDITIONS

16

• PRIVACY POLICY

17

• CONTACT

18

SITEMAP

19

• UNSUBSCRIBE

1	Navigation	HCP websites, <b>link spawns interstitial overlay please refer to appendix A</b>
2	Navigation	Genzyme websites
3	Navigation	Genzyme corporate
4	Navigation	Medication Guide
5	Navigation	Full Prescribing Information
6	Graphic	Logo
7	Copy/CTA	Important safety information, hyperlink will open Full Safety Information
8	Form field	Search
9	Functionality	Change type size

10	CTA	Share the page
11	CTA	Print the page
12	Navigation	About Lemtrada
13	Navigation	What to Expecct
14	Navigation	Resources & Support
15	Navigation	Terms & Conditions, links to outside site
16	Navigation	Privacy policy, links to outside site
17	Navigation	Contact, links to outside site
18	Navigation	Sitemap
19	Navigation	Unsubscribe, links to outside site

• HCP Websites

• Genzyme Websites

• Genzyme Corporate

› Medication Guide

› Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.

[Full Important Safety Information](#)

SEARCH

TYPE SIZE: A **A** A

SHARE

ABOUT LEMTRADA

Why Lemtrada

How Lemtrada Works

Safety & Monitoring

Talking to your Doctor

FAQs

WHAT TO EXPECT

Treatment Steps

Care partner tips

RESOURCES & SUPPORT

Lemtrada Support Offers

Registration

Events

Helpful Resources

Nessim ditatiur, ut re lipid est, et quantus.

Expedic tem sum vid magnis eos dolo dolum faccum inullaut duntias venescid maxim et aut vollissitis et prem. Obitas pereium est, ut excepre henist im alignatem. As atur arum quis ellupta tiusandem quibus duntotatem repudis am in nes molupti busandi geniste eturitem. Magnit, estios iduciunt.

Ficte nus. Ut modis comnimaximi, que volo quunt unt adi dunt, quam ut ipsae eum ad ut possita taspis verum faccatem quature cum earchicipis simenes tiatior ernatur, sapieni quo ea apedit omnis sa dis aciunt et quae vellibu sciant doluptia volor mo inveliqui ommolorro ommolor poreicab invendebis ipicia esequi veruptae venimus quiatet faceaquae eicae eiumet rem autatem nim lacesequae doles dolectem samet volut as ant alibus, audant et faccus exeror sit omnis maximol orehendel illorehent, comnit labor sunt, quibeaturi blatem. Facerae rionsequas adictum rest volupid elicil incienis sed quam utemque offic tem aut accusdae etur aut quam dollam in repeliqui tentiam aut eos ratum quiasit velecepre nost, nonesci litibus nimus quate non ea consequam, quisto ditati cus aut aborro beatque sit eiciure pudiciis qui nus millore stetum debis etur? Pident fugia vent que remolessit, quiscim fuga. Nam, eiur? Qui deliquod et, conempo recusap itaquae nonet aliqui ditiost ad modit vellitatiunt qui inulles temquae. Nam labo. Et a sam reribus aliqui omnis nossedit ut ipsam cum sunt hilitatum nimincimaion rendis eum idesti dollit offic te voleni debit debis dipienim atur si aligendi samus, consequo cora doluptam, aut paribus, comnis doluptam fugitam, qui dem si doluptate consequatio omnisqui vent voluptatem rerum quiam lit, sin cullo volori quae. Nem ressequam recto excesto verro quam vit eum faccaborio testet rae. Obiscietum eari a acest as eos mi, sinullabo. Neque nos et vellacepudi doluptium esequod ut quatibus quunti corepta natur, quidel inulluptam restiur?

Olore nitae ommodit dus es essit eumquis ne es sitiust emporer uptatur, od ut qui offic temossunt faces exereperro molo bea suntia consed estiur, qui dera con plabo. Nequiatus alit ad estorepudi nus id quae offic te molorem que nem eos eatibus et volupta quis sim ipicimilis volupta quatum rerio ipitate sequam evenihition nes eum ex exerchi ligendi tiunt, tem volesequi tet que volor sedis magnam que reruntur, corem veribusanis prereca boriberia comni corerum demporumque ea velibus, sae litaquis quam hitiorum invelig naturitia sapicabor maxim dolendipis et re, velluptas autestiorro tem cust, ute cus ad exces doloruptatia quatos etur, omnia veressi mporehe ndandae iunt harione ssinctaquam qui dessum etur as ma velia qui doluptatur andae suntiam aut aut quam nimi, nonsediae quaerna tiusam, est, quis nus, simporrovita cus eatiis aut quisciet et facitiis doluptis core prepti cum explabo rumquia musant ducil is sunt.

Enis sent. Sanis ma dolorpo riorro exces id moluptatio exerspe repudae ptatur sunt maximus sumque nonserspis explaccus niet exceaqu atibus ero is quias et estio magnimus is nus qui simi, ipit, none is exere cum iusam volor moditem es seri doles et harum nes dusam fuga. Lessitiurem hici ne velit eariandae aut vente doloreped et quia quate con natum, qui deratur autas nonsecaesed es inverfe rionsed et aceriam, qui nis sum nonet eosaperum ipsus excea nobis excea sus voluptame moluptat faceperum volupic tectate ne repuda commolorro vellest quo to berferuntur, sus et, sitiunt la delliqu istiorendita pellanim quatiis voluptae sitibus andipsu mquidebisti dundam, si re sequunda sed ma coria iur, qui ommolectas nestiunt atia volorero dis do-luptae. Sus es di ute di blaboria velibus ditaeri doluptatatus num quodignatur? Is veliqui incit occus sapistiuscid magnatus et voluptat fugit iuribea culles iusa volupta sequis endenisquam vendiate nullo mi, volenimiliae nonecaectur, quatemo lenihil iquostiur, con rest enditatur?

Soluptae dolor min reped ut as explabor ma cum volentis debit audantibus imincius eicient omnis evelique prporpos expliquias mo dolorum et accus invero moluptate cone ne et fuga. Nam consequi rehendae lab idusda dolo ex ea inullabore, consequatem quo explabor ad que latur, sequam as qui diossit modi apitios reiunt, omnihil moluptati dolorib uscitas imaginat emquis rem. Ut aliasint odi dolupta teceatur aut atus andaniam, si unt.

Sante sa velecae dit la aut asinvel magnimus endi dolo ommodi que porere pa dolorio. Cessend elenimpore, sunt, num quod moluptatia quia net et at. Solorro expe niente voluptatiisi a nobit laut officil laboritate eaquist qui testiunt.

Solorpo rionsequid modis dolupti busdaero il il mo exerum que dolorepuda velitas itatem voluptatis perovidit venia vel il et landesto te volupta dolupiciate omnietur seque evel il idendus qui reperib usanti occus et, volupta tectio exceritetur aliae erspelles aut omnihil igendem dolupis explabo. Itatum, inverum fugia nonsequ iandae. Sectas dolorum core comnis re rem re ellabor rovidella pro coriosti susae pa volorat emquiatur, quia dit et maios doluptae etur repudam, si sim re liquist otatusam volupta cus sita volorio nsequam quaepe nonseque optureium haruptassini sequaspiet omniates re nem elibus reheni aut rest aspis essimin estem facero voluptat.

At quid ut rem qui sum quoditatem. Ommos debis ex evel ide volut dolupta tioreni uta dolorem ellores voluptis incidenemque necte volores autae nihicit atempor iorpor aspicism agnaturit volore delis quam net ipsamendae iniention comnis sit iumque pre niendem porerup tatest voluptatur, suntissunt et quisque nonecae nobistecae eum eumqui sunti ut autem nit velliae pratemodi sinciet harum ad quam as enimus pla vid unt.

Igenda vent esecumqui in cor as et quamet dolorer chicil ipidus, offic tem et am iundae porecabo. Ita et etusam faccae ma quam qui occat atquidi ac-cume vellabo. Ut fugitas imust ipsunt laut laborum aut lit int.

Nimagnite exceritius aceperro blaccabore peritia id eaquate pra quid quostiusanis molo ipsandani ut quo illenda conecti voluptate omnimin ctibearum que nobit quae pores nonestibus, offici vellab isquae sequi dis ellest que plam, que molupta nus des qui dolorrovit eatque nonsequ isimpor itation pe neculpa et fugiatur re sint quost, sit alia quatusamet ulparum ad quo illaut qui torporae volorer ferchil modi quis derum faces del ime volupta et elest lati beruntemodis volorepre landa cupta debit doloratio. Xerunde periore icatiis is quodis mos des aut et plicat perum id quiduntibea dolupta nempos as rerum acernate num sumetur, sitatur ad quae odit quae quis et que voluptasitas inverciusdae porrovid et anisci ommo dolor sitatis ium vitat aut aliqui quibeaque plabor samenisim dolum ariaeperrum re nonsed quidusc iendit volecep rovideniendi re volorroviti a plique lam accationsed undi iligniae si unt et veroruptatis solenis corunte volupta volo comniaeste necto mo doluptat faccus autate non pa veruptiatem voluptae nullorio voluptat eum commodite earibus quam verspit esti rae nulparunt que premolu ptatem asped utem vollab inusciandis minia ipsunto quamet pa volor repudae venienet quas am veribusae ped mint, te veligni hiciates con non eaquiatquia sedipsandel ea iminimu saecabo repratur alignim ut magnamus aut que corates sinctat ion-sereraepe electo volor aut alitate stinvenis aliatempori qui solestis est ofofficium id que et maio maxim nia nobit et estet quo qui volorunt.

Consedi tatur, nos aut omnimetur, vendiamus eat volupis ese nest aut que vendebis ad ma aliquid essi quam, qui ut dolent fuga. Cerero ellab ipsa co

TERMS & CONDITIONS • PRIVACY POLICY • CONTACT

SITEMAP • UNSUBSCRIBE

All sub-navigation is accessed via dropdown menus from the main navigation.

HCP Websites

Genzyme Websites

Genzyme Corporate

Medication Guide

Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

SEARCH

TYPE SIZE: A A A

SHARE

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

1

HEADLINE.

Cupessed nos vides fure nonum igitre, Catus hocullatia nonsulario etis ingulemquam o neque mentest rendacchica; ne nihicam pernihilis, nox-impl. Maetis ex mori iderfir tiacci pritumena,

2

3

CTA text link

4

5

Support

6

Events

7

Sign Up

8

9

TITLE

10

11

Cupessed nos vides fure nonum igitre, Catus hocullatia nonsulario etis ingulemquam o neque mentest rendacchica; ne nihicam pernihilis, nox-impl. Maetis ex mori iderfir tiacci pritumena,

12

CTA text link

13

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:

• Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may lead to serious health problems and even death. If detected early, ITP is usually treatable. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms: easy bruising, bleeding from a cut that is hard to stop, heavier menstrual periods than normal, bleeding from your gums or nose that is new or takes longer than usual to stop, or small,scattered spots on your skin that are red, pink, or purple.

• Thyroid disorders. LEMTRADA may cause thyroid disorders, such as an overactive or under active thyroid gland.Thyroid disorders are common and generally manage-able, even though they may require lifelong treatment.Call your healthcare provider if you have any of these symptoms: excessive sweating or feeling cold, unexplained weight loss or weight gain, eye swelling, nervousness, fast heartbeat,worsening tiredness, or newly occurring constipation.

• Kidney disease. LEMTRADA may cause a condition known as antiglomerularbasement membrane(anti-GBM) disease. This can result in severe damage to the kidneys. It can also damage the lungs, although this was not seen in clinical trials withLEMTRADA. If untreated, anti-GBMdisease can cause kidney failure requiring chronic dialysis or transplant,and may lead to death. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms:red or tea-colored urine, swelling in your legs or feet, or coughing up blood.

Monitoring. It is important that you follow your healthcare provider's request for monthly blood and urine tests, so that if side effects associated with LEMTRADA occur, they can be recognized early and treated promptly. It is very important that you continue to have these tests for 4 years after your last LEMTRADA infusion, even if you are feeling well, have no side effects, and your MS symptoms are under control. Some side effects may occur many years after your LEMTRADA treatment and may be life-threatening,so it is very important to continue to follow your healthcare provider's request for regular blood and urine tests and watch out for any symptoms.

Serious infections. LEMTRADA lowers the number of some white blood cells fora period of time after treatment. People with decreased white blood cells may have an increased risk for developing serious infections. Call your healthcare provider right away if you have any signs or symptoms of infection, such as fever,chills, or swollen glands.

LEMTRADA is only available through theAllianceSM Program, which is a restricted distribution program. This means that only prescribers, patients, and healthcare facili-ties enrolled in the Alliance Program can prescribe, receive, and infuseLEMTRADA. To receive LEMTRADA,you must talk to your healthcare provider and understand the benefits and risks of LEMTRADA.

Do not take LEMTRADA if you have human immunodeficiency virus (HIV).

Before taking LEMTRADA, make sure to tell your healthcare provider if:

• You are pregnant or plan to become pregnant, or if you are breastfeeding or plan to breastfeed, as it is not known if LEMTRADA passes into breast milk.You should use effective birth control during and for 4 months after a course of LEMTRADA. If you become pregnant after being treated with LEMTRADA,talk to your healthcare provider about enrolling in the pregnancy registry or call 1-800-XXX-XXXX.

• You have been vaccinated within 6 weeks before receiving a LEMTRADA course or if you wish to be vaccinated after receiving LEMTRADA.

Vaccinations may not be effective if administered directly before or after treatment with LEMTRADA.

• You are taking any medication, including prescription and nonprescription medications, vitamins,and herbal supplements.

Common side effects associated with LEMTRADA, which often occur during or shortly after a single infusion or treatment course, include: headache,rash, fever, nausea, dizziness,vomiting, hives, itching, and difficulty sleeping. Your healthcare provider may recommend medications before your infusion to help reduce and manage your side effects. Other common side effects experienced after a LEMTRADA treatment course include: back pain, an increase in head colds (or in catching the common cold), upper respiratory tract infection, sore throat or mouth pain, feeling tired,urinary tract infection, sinus infection,joint pain, bruising, tingling sensation,and diarrhea.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. You may report side effects by calling 1-800-FDA-1088, or by going to www.fda.gov.

Please see full Prescribing Information,including boxed WARNING, andMedication Guide for LEMTRADA.

TERMS & CONDITIONS

PRIVACY POLICY

CONTACT

SITEMAP

UNSUBSCRIBE

1	Copy	Headline
2	Copy	Body copy
3	Navigation	Call to action, related to con-tent being shown
4	Graphic	Background image
5	Call to action	Support
6	Call to action	Events
7	Call to action	Sign up
8	Call to action	Move to previous content item
9	Copy	Title
10	Graphic	Optional (if needed)

11	Copy	Body copy
12	Navigation	Call to action, drives user to related page
13	Call to action	Move to next content
14	Copy	Disclaimer copy

The middle section functions as a content carousel. As users clicks the CTAs (5-7) the carousel refreshes with the associated content.



HCP Websites

Genzyme Websites

Genzyme Corporate

Medication Guide

Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

SEARCH

TYPE SIZE: A A A

SHARE

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

1

TITLE

Otimissoltili se que tanum estil hilla dum iam es re nis. Et audet vis de aus ia quam in teropote esilicae moru-munum nonsciv ivides pores arimus. It, perfecte facita L. Eposumunt, Catam dementem atus fit.  
Henius hebem, pro et? Sunc mo tantium possolicere, ut viri cus ent vocri intia? Acibulatere vis eruntemultor lii pro etilis, servidi entiam iam iptifec eperebes hae hostanu isum patem et a vius me quam. Ucon audenatum et conlos demusup iendie cepoerete publinat, nox nota, cus ressi pat furs veri silie ret; nontem octam

2

TITLE

Otimissoltili se que tanum estil hilla dum iam es re nis. Et audet vis de aus ia quam in teropote esilicae moru-munum nonsciv ivides pores arimus. It, perfecte facita L. Eposumunt, Catam dementem atus fit.

3

Start exploring the benefits of LEMTRADA :

4

5

Fewer Relapses

6

7

Reduced Disability

8

9

Less Brain Lesions

10

11

Lower Brain Atrophy

12

13

Innovative Treatment Schedule

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:

• Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may lead to serious health problems and even death. If detected early, ITP is usually treatable. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms: easy bruising, bleeding from a cut that is hard to stop, heavier menstrual periods than normal, bleeding from your gums or nose that is new or takes longer than usual to stop, or small,scattered spots on your skin that are red, pink, or purple.

• Thyroid disorders. LEMTRADA may cause thyroid disorders, such as an overactive or under active thyroid gland.Thyroid disorders are common and generally manageable, even though they may require lifelong treatment.Call your healthcare provider if you have any of these symptoms: excessive sweating or feeling cold, unexplained weight loss or weight gain, eye swelling, nervousness, fast heartbeat,worsening tiredness, or newly occurring constipation.

• Kidney disease. LEMTRADA may cause a condition known as antiglomerularbasement membrane(anti-GBM) disease. This can result in severe damage to the kidneys. It can also damage the lungs, although this was not seen in clinical trials withLEMTRADA. If untreated, anti-GBMdisease can cause kidney failure requiring chronic dialysis or transplant,and may lead to death. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms:red or tea-colored urine, swelling in your legs or feet, or coughing up blood.

Monitoring. It is important that you follow your healthcare provider's request for monthly blood and urine tests, so that if side effects associated with LEMTRADA occur, they can be recognized early and treated promptly. It is very important that you continue to have these tests for 4 years after your last LEMTRADA infusion, even if you are feeling well, have no side effects, and your MS symptoms are under control. Some side effects may occur many years after your LEMTRADA treatment and may be life-threatening,so it is very important to continue to follow your healthcare provider's request for regular blood and urine tests and watch out for any symptoms.

Serious infections. LEMTRADA lowers the number of some white blood cells fora period of time after treatment. People with decreased white blood cells may have an increased risk for developing serious infections. Call your healthcare provider right away if you have any signs or symptoms of infection, such as fever,chills, or swollen glands.

LEMTRADA is only available through theAllianceSM Program, which is a restricted distribution program. This means that only prescribers, patients, and healthcare facilities enrolled in the Alliance Program can prescribe, receive, and infuseLEMTRADA. To receive LEMTRADA,you must talk to your healthcare provider and understand the benefits and risks of LEMTRADA.

Do not take LEMTRADA if you have human immunodeficiency virus (HIV).

Before taking LEMTRADA, make sure to tell your healthcare provider if:

• You are pregnant or plan to become pregnant, or if you are breastfeeding or plan to breastfeed, as it is not known if LEMTRADA passes into breast milk.You should use effective birth control during and for 4 months after a course of LEMTRADA. If you become pregnant after being treated with LEMTRADA,talk to your healthcare provider about enrolling in the pregnancy registry or call 1-800-XXX-XXXX.

• You have been vaccinated within 6 weeks before receiving a LEMTRADA course or if you wish to be vaccinated after receiving LEMTRADA.

Vaccinations may not be effective if administered directly before or after treatment with LEMTRADA.

• You are taking any medication, including prescription and nonprescription medications, vitamins,and herbal supplements.

Common side effects associated with LEMTRADA, which often occur during or shortly after a single infusion or treatment course, include: headache,rash, fever, nausea, dizziness,vomiting, hives, itching, and difficulty sleeping. Your healthcare provider may recommend medications before your infusion to help reduce and manage your side effects. Other common side effects experienced after a LEMTRADA treatment course include: back pain, an increase in head colds (or in catching the common cold), upper respiratory tract infection, sore throat or mouth pain, feeling tired,urinary tract infection, sinus infection,joint pain, bruising, tingling sensation,and diarrhea.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. You may report side effects by calling 1-800-FDA-1088, or by going to www.fda.gov.

Please see full Prescribing Information,including boxed WARNING, andMedication Guide for LEMTRADA.

TERMS & CONDITIONS

PRIVACY POLICY

CONTACT

SITEMAP

UNSUBSCRIBE

1	Copy	Title
2	Copy	Body copy
3	Copy	Headline
4	Graphic	
5	Call to action	Fewer relapses
6	Graphic	
7	Call to action	Reduced disability
8	Graphic	
9	Call to action	Less brain lesions
10	Graphic	
11	Call to action	Slower brain atrophy

12	Graphic	
13	Call to action	Innovative treatment schedule
14	Copy	Disclaimer copy

Initial state of this page, transition state shown on next page

• HCP Websites

• Genzyme Websites

• Genzyme Corporate

Medication Guide

Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

SEARCH

TYPE SIZE: A A A

SHARE

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

1

Start exploring the benefits of LEMTRADA :

2

3 Fewer Relapses

4

5 Reduced Disability

6

7 Less Brain Lesions

8

9 Slower Brain Atrophy

10

Innovative Treatment Schedule

11

12

TITLE

13

Otimissoltili se que tanum estil hilla dum iam es re nis. Et audet vis de aus ia 14  
quam in teropote esilicae morumunum nonsciv ivides pores arimus. It, perfecte  
facita L. Eposumunt, Catam dementem atus fit.  
Henius hebem, pro et? Sunc mo tantium possolicere, ut viri cus ent vocri intia?  
Acibulatere vis eruntemultor Iii pro etilis, servidi entiam iam iptifec eperebes hae  
hostanu isum patem et a vius me quam. Ucon audenatum et conlos demusup  
iendie cepoerete publinat, nox nota, cus ressi pat furs veri silie ret; nontem octam

15

16

+ About the Clinical Study

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS). 17

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:

• Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may lead to serious health problems and even death. If detected early, ITP is usually treatable. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms: easy bruising, bleeding from a cut that is hard to stop, heavier menstrual periods than normal, bleeding from your gums or nose that is new or takes longer than usual to stop, or small,scattered spots on your skin that are red, pink, or purple.

• Thyroid disorders. LEMTRADA may cause thyroid disorders, such as an overactive or under active thyroid gland.Thyroid disorders are common and generally manage-able, even though they may require lifelong treatment.Call your healthcare provider if you have any of these symptoms: excessive sweating or feeling cold, unexplained weight loss or weight gain, eye swelling, nervousness, fast heartbeat,worsening tiredness, or newly occurring constipation.

• Kidney disease. LEMTRADA may cause a condition known as antiglomerularbasement membrane(anti-GBM) disease. This can result in severe damage to the kidneys. It can also damage the lungs, although this was not seen in clinical trials withLEMTRADA. If untreated, anti-GBMdisease can cause kidney failure requiring chronic dialysis or transplant,and may lead to death. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms:red or tea-colored urine, swelling in your legs or feet, or coughing up blood.

Monitoring. It is important that you follow your healthcare provider's request for monthly blood and urine tests, so that if side effects associated with LEMTRADA occur, they can be recognized early and treated promptly. It is very important that you continue to have these tests for 4 years after your last LEMTRADA infusion, even if you are feeling well, have no side effects, and your MS symptoms are under control. Some side effects may occur many years after your LEMTRADA treatment and may be life-threatening,so it is very important to continue to follow your healthcare provider's request for regular blood and urine tests and watch out for any symptoms.

Serious infections. LEMTRADA lowers the number of some white blood cells fora period of time after treatment. People with decreased white blood cells may have an increased risk for developing serious infections. Call your healthcare provider right away if you have any signs or symptoms of infection, such as fever,chills, or swollen glands.

LEMTRADA is only available through theAllianceSM Program, which is a restricted distribution program. This means that only prescribers, patients, and healthcare facili-ties enrolled in the Alliance Program can prescribe, receive, and infuseLEMTRADA. To receive LEMTRADA,you must talk to your healthcare provider and understand the benefits and risks of LEMTRADA.

Do not take LEMTRADA if you have human immunodeficiency virus (HIV).

Before taking LEMTRADA, make sure to tell your healthcare provider if:

• You are pregnant or plan to become pregnant, or if you are breastfeeding or plan to breastfeed, as it is not known if LEMTRADA passes into breast milk.You should use effective birth control during and for 4 months after a course of LEMTRADA. If you become pregnant after being treated with LEMTRADA,talk to your healthcare provider about enrolling in the pregnancy registry or call 1-800-XXX-XXXX.

• You have been vaccinated within 6 weeks before receiving a LEMTRADA course or if you wish to be vaccinated after receiving LEMTRADA.

Vaccinations may not be effective if administered directly before or after treatment with LEMTRADA.

• You are taking any medication, including prescription and nonprescription medications, vitamins,and herbal supplements.

Common side effects associated with LEMTRADA, which often occur during or shortly after a single infusion or treatment course, include: headache,rash, fever, nausea, dizziness,vomiting, hives, itching, and difficulty sleeping. Your healthcare provider may recommend medications before your infusion to help reduce and manage your side effects. Other common side effects experienced after a LEMTRADA treatment course include: back pain, an increase in head colds (or in catching the common cold), upper respiratory tract infection, sore throat or mouth pain, feeling tired,urinary tract infection, sinus infection,joint pain, bruising, tingling sensation,and diarrhea.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. You may report side effects by calling 1-800-FDA-1088, or by going to www.fda.gov.

Please see full Prescribing Information,including boxed WARNING, andMedication Guide for LEMTRADA.

TERMS & CONDITIONS • PRIVACY POLICY • CONTACT

SITEMAP • UNSUBSCRIBE

1	Copy	Headline
2	Graphic	
3	Call to action	Fewer relapses
4	Graphic	
5	Call to action	Reduced disability
6	Graphic	
7	Call to action	Less brain lesions
8	Graphic	
9	Call to action	Slower brain atrophy
10	Graphic	
11	Call to action	Innovative treatment schedule

12	Graphic	
13	Copy	Title
14	Copy	Body copy
15	Call to action	Open "About the Clinical Study" copy
16	Call to action	Open "About the Clinical Study" copy
17	Copy	Disclaimer copy

As user scrolls down the page the row of "sub-navigation" within the page docks underneath the global navigation.

• HCP Websites

• Genzyme Websites

• Genzyme Corporate

• Medication Guide

• Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

SEARCH

TYPE SIZE: A A A

SHARE

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

Start exploring the benefits of LEMTRADA :

Fewer Relapses

Reduced Disability

Less Brain Lesions

Slower Brain Atrophy

Innovative Treatment Schedule

TITLE

Otimissoltili se que tanum estil hilla dum iam es re nis. Et audet vis de aus ia quam in teropote esilicae morumunum nonsciv ivides pores arimus. It, perfecte facita L. Eposumunt, Catam dementem atus fit.  
Henius hebem, pro et? Sunc mo tantium possolicere, ut viri cus ent vocri intia? Acibulatere vis eruntemultor Iii pro etilis, servidi entiam iam iptifec eperebes hae hostanu isum patem et a vius me quam. Ucon audenatum et conlos demusup iendie cepoerete publinat, nox nota, cus ressi pat furs veri silie ret; nontem octam

1

2

-

About the Clinical Study

Em volupta sitis quodio iur? Untibeati repra sam elit aut qui dolecto denimol uptat. Solupie nimus, officimus, si tetur?  
Bis aliciet etur aut qui dendia nobis ex eum aut fugit et quatem nonserum essitio. Ibusda andellu ptaquae. Nimilli gendicabor sit omnimus dolupta vellam, si optas nis molestrum qui inventiasped quodioris doluptur? Ri autem sunt il is vel ilit, nat int.  
Senesedit re, torum nobiscipsam, comnis dolupta spedit ipsunt.  
Tatem que pos elendam quosaectem quis nus, sunt vel ini dolecte omnihil iusdam nes numquas earum sunt, sequamendi omnihit ibusci consedis moluptatur alictat dolum volorestisci deruptatur, tem apit auta prem quatum facipsapides experit aut offic tem ut dolupta temquisitis ipiendit aut que et quibeaq uiatque sime dolorro occus sit maios mollaut atempore pa aute velignisit es voluptur sandunt, si reruptatio. Borerae-peles mos autes quatat quaectur sunt am illandis cupta acit, ut fugitaqui aut aute vel ide non postiur? Acesenda sinti am, omnitia spelesc iumquia eum haritini nem fugiae natetur, odic toresti nullaborro illes-tempor acepuda nis dit quaerro qui con re volores rat voluptissin nonsequo que int que officit iatiis eosae il molorem quiatiae pa audio. Ut ullatur assimet ut ea velenihil eum veles re ratet as aut abor audis quis aut velesed icipsuntio. Itas ium et ut el min nis quam quide eni cum, non rero to quae qui conserf erferiore non cus, quam ea quunt laccabo. Laborro tem re rem ab ilignat.  
Sedigenistis suntias dentias simento blaborenti que sequi non pre, volorroviti volum que est mint liquam quiatemolum et as dolupta con re nia de vent maximust, nullam et que excepre stiasit ut arum nullabor mol-lanihit essimod itatisti asped eatio ea consequo voluptio. Di ilit dollandae. Tecusam, voluptatem facepudi sitaten dignim ex es cuptae sim faccae min nobitas vellanis dest moditas perior rempernatur aut dis modic tem ipsapisquias nihit, quam es escipsus cor atem sed quiduntorem repuditium fugiam eicati restio optatis-sum quid ma dolectur aliaecu llaute velitatur, nimus id etur, alicciati que rat ant volupta tenisitet hillandaepra dolut faccus simin explatem acepudi gentore occupa tibeatisci ulpa a qui dolupta temquib eatempos a

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:

• Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may lead to serious health problems and even death. If detected early, ITP is usually treatable. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms: easy bruising, bleeding from a cut that is hard to stop, heavier menstrual periods than normal, bleeding from your gums or nose that is new or takes longer than usual to stop, or small,scattered spots on your skin that are red, pink, or purple.

• Thyroid disorders. LEMTRADA may cause thyroid disorders, such as an overactive or under active thyroid gland.Thyroid disorders are common and generally manageable, even though they may require lifelong treatment.Call your healthcare provider if you have any of these symptoms: excessive sweating or feeling cold, unexplained weight loss or weight gain, eye swelling, nervousness, fast heartbeat,worsening tiredness, or newly occurring constipation.

• Kidney disease. LEMTRADA may cause a condition known as antiglomerularbasement membrane(anti-GBM) disease. This can result in severe damage to the kidneys. It

TERMS & CONDITIONS

• PRIVACY POLICY

• CONTACT

SITEMAP

• UNSUBSCRIBE

1	Call to action	Close "About the Clinical Study" copy
2	Call to action	Close "About the Clinical Study" copy
3	Call to action	Fewer relapses

Shows the functionality of the "About the Clinical Study" call to action.  
*Note, there is no CTA for this functionality under Innovative Treatment schedule.*



HCP Websites

Genzyme Websites

Genzyme Corporate

Medication Guide

Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

SEARCH

TYPE SIZE: A A A

SHARE

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

1

Start exploring the benefits of LEMTRADA :

2

3

Fewer Relapses

4

5

Reduced Disability

6

7

Less Brain Lesions

8

9

Slower Brain Atrophy

10

Innovative Treatment Schedule

11

12

LEMTRADA treatment is just 2 courses over 2 years

13

Most MS treatments are taken daily, weekly, or monthly. LEMTRADA is different— it's given in 2 treatment courses over two years. LEMTRADA is given as an IV (intravenous) infusion.\*

- The first treatment course is given over 5 consecutive days (1 dose per day).
- The second treatment course is given 12 months later on 3 consecutive days (1 dose per day).

After the first treatment course, monthly lab tests are required to monitor for long-term side effects. You'll need to continue these lab tests for four years after the last course.  
  
\*An IV infusion is when medication is given through a needle generally placed in a vein in your arm.

14

ms one to one

Get information, resources and more from LEMTRADA support at MS One to One®.

LEARN MORE

17

DOCTOR DISCUSSION GUIDE

Take this guide to your next appointment to help start the conversation about LEMTRADA.

GET THE GUIDE

COURSE 1

COURSE 2

12 MONTHS LATER

20

LEARN HOW LEMTRADA WORKS >

21

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

22

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:

- Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may lead to serious health problems and even death. If detected early, ITP is usually treatable. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms: easy bruising, bleeding from a cut that is hard to stop, heavier menstrual periods than normal, bleeding from your gums or nose that is new or takes longer than usual to stop, or small,scattered spots on your skin that are red, pink, or purple.
- Thyroid disorders. LEMTRADA may cause thyroid disorders, such as an overactive or under active thyroid gland.Thyroid disorders are common and generally manage-able, even though they may require lifelong treatment.Call your healthcare provider if you have any of these symptoms: excessive sweating or feeling cold, unexplained weight loss or weight gain, eye swelling, nervousness, fast heartbeat,worsening tiredness, or newly occurring constipation.
- Kidney disease. LEMTRADA may cause a condition known as antiglomerularbasement membrane(anti-GBM) disease. This can result in severe damage to the kidneys. It can also damage the lungs, although this was not seen in clinical trials withLEMTRADA. If untreated, anti-GBMdisease can cause kidney failure requiring chronic dialysis or transplant,and may lead to death. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms:red or tea-colored urine, swelling in your legs or feet, or coughing up blood.

Monitoring. It is important that you follow your healthcare provider's request for monthly blood and urine tests, so that if side effects associated with LEMTRADA occur, they can be recognized early and treated promptly. It is very important that you continue to have these tests for 4 years after your last LEMTRADA infusion, even if you are feeling well, have no side effects, and your MS symptoms are under control. Some side effects may occur many years after your LEMTRADA treatment and may be life-threatening,so it is very important to continue to follow your healthcare provider's request for regular blood and urine tests and watch out for any symptoms. Serious infections. LEMTRADA lowers the number of some white blood cells fora period of time after treatment. People with decreased white blood cells may have an increased risk for developing serious infections. Call your healthcare provider right away if you have any signs or symptoms of infection, such as fever,chills, or swollen glands. LEMTRADA is only available through theAllianceSM Program, which is a restricted distribution program. This means that only prescribers, patients, and healthcare facili-ties enrolled in the Alliance Program can prescribe, receive, and infuseLEMTRADA. To receive LEMTRADA,you must talk to your healthcare provider and understand the benefits and risks of LEMTRADA. Do not take LEMTRADA if you have human immunodeficiency virus (HIV).

TERMS & CONDITIONS

PRIVACY POLICY

CONTACT

SITEMAP

UNSUBSCRIBE

1	Copy	Headline
2	Graphic	
3	Call to action	Fewer relapses
4	Graphic	
5	Call to action	Reduced disability
6	Graphic	
7	Call to action	Less brain lesions
8	Graphic	
9	Call to action	Slower brain atrophy
10	Graphic	
11	Call to action	Innovative treatment schedule
12	Copy	Header

13	Copy	Body copy
14	Graphic	
15	Copy	Body copy
16	Call to action	Takes user to MS 1 to 1
17	Graphic	
18	Copy	Body copy
19	Call to action	Takes user to Doctor's Dis-cussion Guide
20	Graphic	
21	Navigation	Take user to learn how Lem-trada works page
22	Copy	Disclaimer copy



HCP Websites

Genzyme Websites

Genzyme Corporate

Medication Guide

Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

SEARCH

TYPE SIZE: A A A

SHARE

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

1

LEMTRADA works differently

2

Tatenditi audam vel est ad quid molorerum fugia quatus, omnis atibea ped expediscid errum volenti onestorpore endistorest, cuptaqu aeptatiusci dere nobis perum vendaec estiam, conse millaut res nossimus experem facestia archili gnihit ipiciis el magniste pra consed ma sitis int vid ullam laboreh endiciustisi sam resequosam fuga. Nam rectectem eictotatem est utes re recae nonsequi quistem. Nempor maximpore debit officium que eium voluptiisit, si re, sus poribus entotat aligent porem. Ut

3

1

4

RECOGNIZE

5

Lemtrada : Ist, quos a cus et reicae evelest incium nos dolor aut quistium ipsae expedis sit et optatia diciendendit voles sedis nullo

6

7

2

8

REMOVE

9

Lemtrada : Ist, quos a cus et reicae evelest incium nos dolor aut quistium ipsae expedis sit et optatia diciendendit voles sedis nullo volorem arum inc

10

11

3

12

REBUILD

13

Lemtrada : Ist, quos a cus et reicae evelest incium nos dolor aut quistium ipsae expedis sit et optatia diciendendit voles sedis nullo volorem arum inc

14

15

LEARN ABOUT SAFETY & MONITORING >

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

16

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:

• Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may lead to serious health problems and even death. If detected early, ITP is usually treatable. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms: easy bruising, bleeding from a cut that is hard to stop, heavier menstrual periods than normal, bleeding from your gums or nose that is new or takes longer than usual to stop, or small,scattered spots on your skin that are red, pink, or purple.

• Thyroid disorders. LEMTRADA may cause thyroid disorders, such as an overactive or under active thyroid gland.Thyroid disorders are common and generally manage-able, even though they may require lifelong treatment.Call your healthcare provider if you have any of these symptoms: excessive sweating or feeling cold, unexplained weight loss or weight gain, eye swelling, nervousness, fast heartbeat,worsening tiredness, or newly occurring constipation.

• Kidney disease. LEMTRADA may cause a condition known as antiglomerularbasement membrane(anti-GBM) disease. This can result in severe damage to the kidneys. It can also damage the lungs, although this was not seen in clinical trials withLEMTRADA. If untreated, anti-GBMdisease can cause kidney failure requiring chronic dialysis or transplant,and may lead to death. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms:red or tea-colored urine, swelling in your legs or feet, or coughing up blood.

Monitoring. It is important that you follow your healthcare provider’s request for monthly blood and urine tests, so that if side effects associated with LEMTRADA occur, they can be recognized early and treated promptly. It is very important that you continue to have these tests for 4 years after your last LEMTRADA infusion, even if you are feeling well, have no side effects, and your MS symptoms are under control. Some side effects may occur many years after your LEMTRADA treatment and may be life-threatening,so it is very important to continue to follow your healthcare provider’s request for regular blood and urine tests and watch out for any symptoms.

Serious infections. LEMTRADA lowers the number of some white blood cells fora period of time after treatment. People with decreased white blood cells may have an increased risk for developing serious infections. Call your healthcare provider right away if you have any signs or symptoms of infection, such as fever,chills, or swollen glands.

LEMTRADA is only available through theAllianceSM Program, which is a restricted distribution program. This means that only prescribers, patients, and healthcare facili-ties enrolled in the Alliance Program can prescribe, receive, and infuseLEMTRADA. To receive LEMTRADA,you must talk to your healthcare provider and understand the benefits and risks of LEMTRADA.

Do not take LEMTRADA if you have human immunodeficiency virus (HIV).

TERMS & CONDITIONS

PRIVACY POLICY

CONTACT

SITEMAP

UNSUBSCRIBE

1	Copy	Headline
2	Copy	Body copy
3	Graphic	
4	Copy	Headline
5	Copy	Body copy
6	Graphic	
7	Graphic	
8	Copy	Headline
9	Copy	Body copy
10	Graphic	
11	Graphic	

12	Copy	Headline
13	Copy	Body copy
14	Graphic	
15	Navigation	Learn about Safety & Monitoring
16	Copy	Disclaimer copy

ABOUT LEMTRADA

GETTING STARTED

RESOURCES & SUPPORT

2

REMOVE

Lemtrada : Ist, quos a cus et reicae evelest incium nos dolor aut quistium ipsae expedis sit et optatia diciendendit voles sedis nullo volorem arum inc

3

REBUILD

Lemtrada : Ist, quos a cus et reicae evelest incium nos dolor aut quistium ipsae expedis sit et optatia diciendendit voles sedis nullo volorem arum inc

LEARN ABOUT SAFETY & MONITORING >

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:

• Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may lead to serious health problems and even death. If detected early, ITP is usually treatable. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms: easy bruising, bleeding from a cut that is hard to stop, heavier menstrual periods than normal, bleeding from your gums or nose that is new or takes longer than usual to stop, or small,scattered spots on your skin that are red, pink, or purple.

• Thyroid disorders. LEMTRADA may cause thyroid disorders, such as an overactive or under active thyroid gland.Thyroid disorders are common and generally manageable, even though they may require lifelong treatment.Call your healthcare provider if you have any of these symptoms: excessive sweating or feeling cold, unexplained weight loss or weight gain, eye swelling, nervousness, fast heartbeat,worsening tiredness, or newly occurring constipation.

• Kidney disease. LEMTRADA may cause a condition known as antiglomerularbasement membrane(anti-GBM) disease. This can result in severe damage to the kidneys. It can also damage the lungs, although this was not seen in clinical trials withLEMTRADA. If untreated, anti-GBMdisease can cause kidney failure requiring chronic dialysis or transplant,and may lead to death. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms:red or tea-colored urine, swelling in your legs or feet, or coughing up blood.

Monitoring. It is important that you follow your healthcare provider’s request for monthly blood and urine tests, so that if side effects associated with LEMTRADA occur, they can be recognized early and treated promptly. It is very important that you continue to have these tests for 4 years after your last LEMTRADA infusion, even if you are feeling well, have no side effects, and your MS symptoms are under control. Some side effects may occur many years after you receive your last LEMTRADA treatment and may be life-threatening,so it is very important to continue to follow your healthcare provider’s request for regular blood and urine tests and watch out for any symptoms.

Serious infections. LEMTRADA lowers the number of some white blood cells fora period of time after treatment. People with decreased white blood cells may have an increased risk for developing serious infections. Call your healthcare provider right away if you have any signs or symptoms of infection, such as fever,chills, or swollen glands.

LEMTRADA is only available through theAllianceSM Program, which is a restricted distribution program. This means that only prescribers, patients, and healthcare facilities enrolled in the Alliance Program can prescribe, receive, and infuseLEMTRADA. To receive LEMTRADA,you must talk to your healthcare provider and understand the benefits and risks of LEMTRADA.

Do not take LEMTRADA if you have human immunodeficiency virus (HIV).

CONTACT • SITEMAP

TERMS & CONDITIONS •

This page is meant to show the the interaction design of the "How Lemtrada Works"landing page.

On initial display the global navigation appears in its usual place beneath the header, and the three panels display below in a semi-open state.

As the user scrolls down the page the global navigation docks at the top and the first panel begins its reveal.

The display panels reveal and animate as the user scrolls down the page.

Once the user scrolls has scrolled through all of the display panels, they stay open for the duration of the sessions.

If the user scrolls all the way to the top the header will reappear and the global navigation will dock beneath in its usual position.

This site is intended for United States residents only.

Medication GuidePrescribing InformationU.S. Healthcare Professionals Site

Genzyme CorporateGenzyme Websites

ShareType size: A A Search

LEMTRADA

alemtuzumab

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. [Full Important Safety Information](#)

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

LEMTRADA WORKS DIFFERENTLY

MS occurs when immune cells stop protecting and start attacking. Your immune system protects you from foreign invaders like bacteria and viruses. But when you have MS, the cells of your immune system that normally work as protectors get confused and mistakenly attack healthy parts of your central nervous system such as your brain, spinal cord, and the optic nerve behind your eyes.

LEMTRADA targets the cells thought to cause MS

How LEMTRADA works is different because it works to remove the cells that are thought to cause MS symptoms.

1

RECOGNIZE

2

REMOVE

LEMTRADA

alemtuzumab

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. [Full Important Safety Information](#)

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

LEMTRADA WORKS DIFFERENTLY

MS occurs when immune cells stop protecting and start attacking. Your immune system protects you from foreign invaders like bacteria and viruses. But when you have MS, the cells of your immune system that normally work as protectors get confused and mistakenly attack healthy parts of your central nervous system such as your brain, spinal cord, and the optic nerve behind your eyes.

LEMTRADA targets the cells thought to cause MS

How LEMTRADA works is different because it works to remove the cells that are thought to cause MS symptoms.

1

RECOGNIZE

2

REMOVE

3

REBUILD

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

LEMTRADA WORKS DIFFERENTLY

MS occurs when immune cells stop protecting and start attacking. Your immune system protects you from foreign invaders like bacteria and viruses. But when you have MS, the cells of your immune system that normally work as protectors get confused and mistakenly attack healthy parts of your central nervous system such as your brain, spinal cord, and the optic nerve behind your eyes.

LEMTRADA targets the cells thought to cause MS

How LEMTRADA works is different because it works to remove the cells that are thought to cause MS symptoms.

1

RECOGNIZE

2

REMOVE

3

REBUILD

INDICATION

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

from foreign invaders like bacteria and viruses. But when you have MS, the cells of your immune system that normally work as protectors get confused and mistakenly attack healthy parts of your central nervous system such as your brain, spinal cord, and the optic nerve behind your eyes.

LEMTRADA targets the cells thought to cause MS

How LEMTRADA works is different because it works to remove the cells that are thought to cause MS symptoms.

1

RECOGNIZE

LEMTRADA will recognize certain immune cells in your body, including those thought to cause MS.

2

REMOVE

3

REBUILD

INDICATION

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

LEMTRADA targets the cells thought to cause MS

How LEMTRADA works is different because it works to remove the cells that are thought to cause MS symptoms.

1

RECOGNIZE

LEMTRADA will recognize certain immune cells in your body, including those thought to cause MS.

2

REMOVE

3

REBUILD

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

immune cells in your body, including those thought to cause MS.

Harmful immune cells

2

REMOVE

LEMTRADA will remove many of those cells. Other immune cells will still be in your body to protect you.

3

REBUILD

After treatment, your immune system will slowly rebuild on its own, growing new cells.

INDICATION

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

2

REMOVE

LEMTRADA will remove many of those cells. Other immune cells will still be in your body to protect you.

3

REBUILD

After treatment, your immune system will slowly rebuild on its own, growing new cells.

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

IMPORTANT SAFETY INFORMATION

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

LEMTRADA will remove many of those cells. Other immune cells will still be in your body to protect you.

3

REBUILD

After treatment, your immune system will slowly rebuild on its own, growing new cells.

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects.

Immune thrombocytopenic purpura (ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may lead to serious health problems and even death. If detected early, ITP is usually treatable. Call your healthcare





• HCP Websites

• Genzyme Websites

• Genzyme Corporate

• Medication Guide

• Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

SEARCH

TYPE SIZE: A A A

SHARE

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

1

Talking to your doctor

2

Tatenditi audam vel est ad quid molorerum fugia quatus, omnis atibea ped expediscid errum volenti onestorpore endistorest, cuptaqu aeptatiusci dere nobis perum vendaec estiam, conse millaut res nossimus experem facestia archili gnihit ipiciis el magniste pra consed ma sitis int vid ullam laboreh

3

4

5

Type in your answers and print out the guide

Or print out the guide first and write your answers by hand.  
Then take the guide with you to your next doctor visit.

6

DOCTOR DISCUSSION GUIDE

7

1. Text of the question here?

2. Text of the question here?

3. Text of the question here?

4. Text of the question here?

5. Text of the question here?

6. Text of the question here?

7. Text of the question here?

8. Text of the question here?

9. Text of the question here?

8

Questions for you doctor

9

1. Text of the question here? Lum voluptate voluptaque ommo eos ea nobisquam ius aut iliqui qui doluptatet autaspe et

2. Text of the question here? Lum voluptate voluptaque ommo eos ea nobisquam ius aut iliqui qui doluptatet autaspe et

3. Text of the question here? Lum voluptate voluptaque ommo eos ea nobisquam ius aut iliqui qui doluptatet autaspe et

4. Text of the question here? Lum voluptate voluptaque ommo eos ea nobisquam ius aut iliqui qui doluptatet autaspe et

10

Print out the discussion guide and share it with your doctor.

11

Download >

12

Print Now >

LEARN ABOUT TREATMENT STEPS >

13

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

14

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:

• Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may lead to serious health problems and even death. If detected early, ITP is usually treatable. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms: easy bruising, bleeding from a cut that is hard to stop, heavier menstrual periods than normal, bleeding from your gums or nose that is new or takes longer than usual to stop, or small,scattered spots on your skin that are red, pink, or purple.

• Thyroid disorders. LEMTRADA may cause thyroid disorders, such as an overactive or under active thyroid gland.Thyroid disorders are common and generally manage-able, even though they may require lifelong treatment.Call your healthcare provider if you have any of these symptoms: excessive sweating or feeling cold, unexplained weight loss or weight gain, eye swelling, nervousness, fast heartbeat,worsening tiredness, or newly occurring constipation.

• Kidney disease. LEMTRADA may cause a condition known as antiglomerularbasement membrane(anti-GBM) disease. This can result in severe damage to the kidneys. It can also damage the lungs, although this was not seen in clinical trials withLEMTRADA. If untreated, anti-GBMdisease can cause kidney failure requiring chronic dialysis or transplant,and may lead to death. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms:red or tea-

TERMS & CONDITIONS

• PRIVACY POLICY

• CONTACT

SITEMAP

• UNSUBSCRIBE

1	Copy	Title
2	Copy	Body copy
3	Graphic	Background image
4	Graphic	
5	Copy	Explanatory copy
6	Copy	Title
7	Copy	Question
8	Copy	Headline
9	Copy	Question copy
10	Copy	

11	Call to action	Download the pdf
12	Call to action	Print the page
13	Navigation	Takes user to treatment steps
14	Copy	Disclaimer copy

• HCP Websites

• Genzyme Websites

• Genzyme Corporate

• Medication Guide

• Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

TYPE SIZE: A

A

SHARE

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

1

Frequently Asked Questions

2

+

Expand All

3

4

+

Question 1 text here?

5

+

And then the text for question here?

+

Question 1 text here?

+

And then the text for question here?

+

Question 1 text here?

+

And then the text for question here?

+

Question 1 text here?

+

And then the text for question here?

6

-

Question 1 text here?

7

Sequasiment facile ntist, numet illes sed experio occat vel ipsae porest, to odis experum invent voluptae qui tendigen-dae et officae stium, estiatur aliqui blamet ium laboremquis et eatiae commo con perrum fuga. Neque odit lant dolupta tioreperrum fugitia dolupta veriam que re magnate commol-or mi, corro ventia dio est laborestrum con consequia sam dunt event quas aut eume nobis quis estisit, audam qui

8

9

DOCTOR DISCUSSION GUIDE

Take this guide to your next appointment to help start the conversation about LEMTRADA.

10

11

GET THE GUIDE

12

ms one to one

Get information, resources and more from LEMTRADA support at MS One to One®.

13

14

LEARN MORE

LEARN ABOUT TREATMENT STEPS >

15

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:

• Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may lead to serious health problems and even death. If detected early, ITP is usually treatable. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms: easy bruising, bleeding from a cut that is hard to stop, heavier menstrual periods than normal, bleeding from your gums or nose that is new or takes longer than usual to stop, or small,scattered spots on your skin that are red, pink, or purple.

• Thyroid disorders. LEMTRADA may cause thyroid disorders, such as an overactive or under active thyroid gland.Thyroid disorders are common and generally manage-able, even though they may require lifelong treatment.Call your healthcare provider if you have any of these symptoms: excessive sweating or feeling cold, unexplained weight loss or weight gain, eye swelling, nervousness, fast heartbeat,worsening tiredness, or newly occurring constipation.

• Kidney disease. LEMTRADA may cause a condition known as antiglomerularbasement membrane(anti-GBM) disease. This can result in severe damage to the kidneys. It can also damage the lungs, although this was not seen in clinical trials withLEMTRADA. If untreated, anti-GBMdisease can cause kidney failure requiring chronic dialysis or transplant,and may lead to death. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms:red or tea-colored urine, swelling in your legs or feet, or coughing up blood.

Monitoring. It is important that you follow your healthcare provider’s request for monthly blood and urine tests, so that if side effects associated with LEMTRADA occur, they can be recognized early and treated promptly. It is very important that you continue to have these tests for 4 years after your last LEMTRADA infusion, even if you are feeling well, have no side effects, and your MS symptoms are under control. Some side effects may occur many years after your LEMTRADA treatment and may be life-threatening,so it is very important to continue to follow your healthcare provider’s request for regular blood and urine tests and watch out for any symptoms.

Serious infections. LEMTRADA lowers the number of some white blood cells fora period of time after treatment. People with decreased white blood cells may have an increased risk for developing serious infections. Call your healthcare provider right away if you have any signs or symptoms of infection, such as fever,chills, or swollen glands.

LEMTRADA is only available through theAllianceSM Program, which is a restricted distribution program. This means that only prescribers, patients, and healthcare facili-ties enrolled in the Alliance Program can prescribe, receive, and infuseLEMTRADA. To receive LEMTRADA,you must talk to your healthcare provider and understand the

16

TERMS & CONDITIONS

•

PRIVACY POLICY

•

CONTACT

SITEMAP

•

UNSUBSCRIBE

1	Copy	Title
2	Call to action	Open all questions, if user opens all questions this re-verts to a "-" symbol
3	Copy	
4	Call to action	Open the question, if user opens all questions this re-verts to a "-" symbol
5	Copy	
6	Call to action	Close the question, if user opens all questions this re-verts to a "+" symbol
7	Copy	

8	Copy	Body copy
9	Graphic	
10	Copy	Body copy
11	Call to action	Takes user to Doctor's Discus-sion Guide
12	Graphic	
13	Copy	Body copy
14	Call to action	Takes user to MS 1 to 1
15	Navigation	Takes user to treatment steps
16	Copy	Disclaimer copy

• HCP Websites

• Genzyme Websites

• Genzyme Corporate

• Medication Guide

• Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

SEARCH

TYPE SIZE: A A A

SHARE

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

1

YOUR LEMTRADA TREATMENT JOURNEY

2

3 Planning

4

5 Before Treatment

6

7 Treatment

8

9 After Treatment

10

Cervidesite cri te cricerf econveh ebatiemedo, supio, nuniqonem, nes inces hocam pos ceporiam convoli casdamendam, furnihi listrem, Catuius, quides viura publicitio,

11

SCROLL

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:

• Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may lead to serious health problems and even death. If detected early, ITP is usually treatable. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms: easy bruising, bleeding from a cut that is hard to stop, heavier menstrual periods than normal, bleeding from your gums or nose that is new or takes longer than usual to stop, or small,scattered spots on your skin that are red, pink, or purple.

• Thyroid disorders. LEMTRADA may cause thyroid disorders, such as an overactive or under active thyroid gland.Thyroid disorders are common and generally manageable, even though they may require lifelong treatment.Call your healthcare provider if you have any of these symptoms: excessive sweating or feeling cold, unexplained weight loss or weight gain, eye swelling, nervousness, fast heartbeat,worsening tiredness, or newly occurring constipation.

• Kidney disease. LEMTRADA may cause a condition known as antiglomerularbasement membrane(anti-GBM) disease. This can result in severe damage to the kidneys. It can also damage the lungs, although this was not seen in clinical trials withLEMTRADA. If untreated, anti-GBMdisease can cause kidney failure requiring chronic dialysis or transplant,and may lead to death. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms:red or tea-colored urine, swelling in your legs or feet, or coughing up blood.

Monitoring. It is important that you follow your healthcare provider's request for monthly blood and urine tests, so that if side effects associated with LEMTRADA occur, they can be recognized early and treated promptly. It is very important that you continue to have these tests for 4 years after your last LEMTRADA infusion, even if you are feeling well, have no side effects, and your MS symptoms are under control. Some side effects may occur many years after your LEMTRADA treatment and may be life-threatening,so it is very important to continue to follow your healthcare provider's request for regular blood and urine tests and watch out for any symptoms.

Serious infections. LEMTRADA lowers the number of some white blood cells fora period of time after treatment. People with decreased white blood cells may have an increased risk for developing serious infections. Call your healthcare provider right away if you have any signs or symptoms of infection, such as fever,chills, or swollen glands.

LEMTRADA is only available through theAllianceSM Program, which is a restricted distribution program. This means that only prescribers, patients, and healthcare facilities enrolled in the Alliance Program can prescribe, receive, and infuseLEMTRADA. To receive LEMTRADA,you must talk to your healthcare provider and understand the benefits and risks of LEMTRADA.

Do not take LEMTRADA if you have human immunodeficiency virus (HIV).

Before taking LEMTRADA, make sure to tell your healthcare provider if:

• You are pregnant or plan to become pregnant, or if you are breastfeeding or plan to breastfeed, as it is not known if LEMTRADA passes into breast milk.You should use effective birth control during and for 4 months after a course of LEMTRADA. If you become pregnant after being treated with LEMTRADA,talk to your healthcare provider about enrolling in the pregnancy registry or call 1-800-XXX-XXXX.

• You have been vaccinated within 6 weeks before receiving a LEMTRADA course or if you wish to be vaccinated after receiving LEMTRADA.

Vaccinations may not be effective if administered directly before or after treatment with LEMTRADA.

• You are taking any medication, including prescription and nonprescription medications, vitamins,and herbal supplements.

Common side effects associated with LEMTRADA, which often occur during or shortly after a single infusion or treatment course, include: headache,rash, fever, nausea, dizziness,vomiting, hives, itching, and difficulty sleeping. Your healthcare provider may recommend medications before your infusion to help reduce and manage your side effects. Other common side effects experienced after a LEMTRADA treatment course include: back pain, an increase in head colds (or in catching the common cold), upper respiratory tract infection, sore throat or mouth pain, feeling tired,urinary tract infection, sinus infection,joint pain, bruising, tingling sensation,and diarrhea.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. You may report side effects by calling 1-800-FDA-1088, or by going to www.fda.gov.

Please see full Prescribing Information,including boxed WARNING, andMedication Guide for LEMTRADA.

TERMS & CONDITIONS

• PRIVACY POLICY

• CONTACT

SITEMAP

• UNSUBSCRIBE

1	Copy	Headline
2	Call to action / Graphic	
3	Call to action / Copy	Planning
4	Call to action / Graphic	
5	Call to action / Copy	Before Treatment
6	Call to action / Graphic	
7	Call to action / Copy	Treatment
8	Call to action / Graphic	
9	Call to action / Copy	After Treatment
10	Copy	Body copy
11	Call to acton	Scroll

12	Copy	Disclaimer copy
----	------	-----------------

This page functions as a "parallax" view.

The calls to action function two-fold (1) as a call to action that allows the user to jump to that specific area & (2) as visual indicators. As the user scrolls or clicks that specific section, the CTA's graphic and text are highlighted.



ABOUT LEMTRADA

GETTING STARTED

RESOURCES & SUPPORT

1

YOUR LEMTRADA TREATMENT JOURNEY

2

3

Planning

4

5

Before Treatment

6

7

Treatment

8

9

Before Treatment

10

TREATMENT

11

On the days of your infusion.

A healthcare provider will give you your LEMTRADA as an intravenous (IV) infusion. An IV infusion is when medication is given through a needle generally placed in a vein in your arm.

Some people may experience side effects during the infusion, such as headache, rash, fever, or nausea. Your doctor may prescribe medications before your infusion to make infusion side effects less likely.

How long will it take?

Each infusion takes approximately 4 hours. Some people like to read or listen to music during this time.

After your infusion, your healthcare provider will monitor you for 2 hours to make sure you don't have any side effects.

13

Fold

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:

• Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may

CONTACT • SITEMAP

TERMS & CONDITIONS • PRIVACY POLICY • UNSUBSCRIBE

1	Copy	Headline
2	Call to action / Graphic	
3	Call to action / Copy	Planning
4	Call to action / Graphic	
5	Call to action / Copy	Before Treatment
6	Call to action / Graphic	
7	Call to action / Copy	Treatment
8	Call to action / Graphic	
9	Call to action / Copy	After Treatment
10	Graphic	Visual Indicator
11	Copy	Title

12	Copy	Body copy
13	Graphic	Background image
14	Copy	Disclaimer copy

This page functions as a "parallax" view.

The calls to action function two-fold (1) as a call to action that allows the user to jump to that specific area & (2) as visual indicators. As the user scrolls or clicks that specific section, the CTA's graphic and text are highlighted.



• HCP Websites

• Genzyme Websites

• Genzyme Corporate

› Medication Guide

› Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

TYPE SIZE: A A A

SHARE

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

1

CARE PARTNER TIPS

2

Cervidesite cri te cricerf econveh ebatiedo, supio, nuniqonem, nes inces hocam pos ceporiam convoli casdamendam, furnihi listrem, Catuius, quides viura publicitio,

- At et hil explicto temolup tasperspero voluptur as sequunt.Re dernasque dolor-em rempero deriscima accus eum et que soloriberrum aut ut et fugit fuga. Atium ereicat.
- Od et, ut quaes rererio. Magnimu santibus volum anis same seque nus, unt es non es arum, nust laut lit, odit earios abor sintore et amusa volore, simin reicte nus.
- Ficidernati dolorem vellorum ipsusdae et ide vollent ab imi, non ex estiatum que niet aut re nimoloribus inis autas andem idit perem in nulparciunti aut doluptat.
- Utem duciliqui dolore audition ex eveliqu atisquas sa est, sum simust, quodita de que nus.
- Magnis sim sequia quatatam quodisinctet et as es denim core nimilitat.Int mo-luptatia nosa nectes est, odignatibus et laut aliquatur? Ut ipsandaepedi temolor epelendae as sit, sam haruptatur? Quia conectem etum dolorep eroris rentis alis-susa quiduntem quatquatur sit eos arum dolupis arciatia in prendendem ipis et videm doluptas es ipsandaepudi temporit ma velique provit eos dolor
- rerum faciti rae. Nam veni nat audam lam doluptatibus is volore optatur aria por-est, cusdam re paritiate rem quidus aliqui occaturis ad qui vit, te quaspiendaes illabor sapis dolorem eumquodi tore voluptae nossimp oresciisqui omni as in con pari quae con nonseriscia parupta deris cus endantur aut dolum autatem hit, cus, eos audit quam, totat officid estinvent isquos eruptas ipsande officiandist aci dem voloriae essi apis re simaione vent, soluptias quatus im cullace ritius aut vit dolupta turepedi cum, nimi, es dolora voluptur sit autem a voluptur?accus et di ut unt millore icipica epercient as pro dit asi cus voluptate vellanto

3

ms one to one

a

b

Get information, resources and more from LEMTRADA support at MS One to One®.

LEARN MORE >

c

4

LEMTRADA EVENTS

a

b

c

Attend free, local events about the latest in MS treatment

GET THE GUIDE >

5

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:

- Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may lead to serious health problems and even death. If detected early, ITP is usually treatable. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms: easy bruising, bleeding from a cut that is hard to stop, heavier menstrual periods than normal, bleeding from your gums or nose that is new or takes longer than usual to stop, or small,scattered spots on your skin that are red, pink, or purple.
- Thyroid disorders. LEMTRADA may cause thyroid disorders, such as an overactive or under active thyroid gland.Thyroid disorders are common and generally manage-able, even though they may require lifelong treatment.Call your healthcare provider if you have any of these symptoms: excessive sweating or feeling cold, unexplained weight loss or weight gain, eye swelling, nervousness, fast heartbeat,worsening tiredness, or newly occurring constipation.
- Kidney disease. LEMTRADA may cause a condition known as antglomerularbasement membrane(anti-GBM) disease. This can result in severe damage to the kidneys. It can also damage the lungs, although this was not seen in clinical trials withLEMTRADA. If untreated, anti-GBMdisease can cause kidney failure requiring chronic dialysis or transplant,and may lead to death. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms:red or tea-colored urine, swelling in your legs or feet, or coughing up blood.

Monitoring. It is important that you follow your healthcare provider’s request for monthly blood and urine tests, so that if side effects associated with LEMTRADA occur, they can be recognized early and treated promptly. It is very important that you continue to have these tests for 4 years after your last LEMTRADA infusion, even if you are feeling well, have no side effects, and your MS symptoms are under control. Some side effects may occur many years after your LEMTRADA treatment and may be life-threatening,so it is very important to continue to follow your healthcare provider’s request for regular blood and urine tests and watch out for any symptoms.

Serious infections. LEMTRADA lowers the number of some white blood cells fora period of time after treatment. People with decreased white blood cells may have an increased risk for developing serious infections. Call your healthcare provider right away if you have any signs or symptoms of infection, such as fever,chills, or swollen glands.

LEMTRADA is only available through theAllianceSM Program, which is a restricted distribution program. This means that only prescribers, patients, and healthcare facili-ties enrolled in the Alliance Program can prescribe, receive, and infuseLEMTRADA. To receive LEMTRADA,you must talk to your healthcare provider and understand the benefits and risks of LEMTRADA.

Do not take LEMTRADA if you have human immunodeficiency virus (HIV).

Before taking LEMTRADA, make sure to tell your healthcare provider if:

- You are pregnant or plan to become pregnant, or if you are breastfeeding or plan to breastfeed, as it is not known if LEMTRADA passes into breast milk.You should use effective birth control during and for 4 months after a course of LEMTRADA. If you become pregnant after being treated with LEMTRADA,talk to your healthcare provider about enrolling in the pregnancy registry or call 1-800-XXX-XXXX.
- You have been vaccinated within 6 weeks before receiving a LEMTRADA course or if you wish to be vaccinated after receiving LEMTRADA.

Vaccinations may not be effective if administered directly before or after treatment with LEMTRADA.

- You are taking any medication, including prescription and nonprescription medications, vitamins,and herbal supplements.

Common side effects associated with LEMTRADA, which often occur during or shortly after a single infusion or treatment course, include: headache,rash, fever, nausea, dizziness,vomiting, hives, itching, and difficulty sleeping. Your healthcare provider may recommend medications before your infusion to help reduce and manage your side effects. Other common side effects experienced after a LEMTRADA treatment course include: back pain, an increase in head colds (or in catching the common cold), upper

TERMS & CONDITIONS • PRIVACY POLICY • CONTACT

SITEMAP • UNSUBSCRIBE

1	Copy	Title
2	Copy	Body copy
3	MS 1 to 1 lockup	
3a	Graphic	
3b	Copy	Body copy
3c	Navigation	Takes user to MS 1 to 1 page
4	Lemtrada Events	
4a	Graphic	
4b	Copy	Body copy
4c	Navigation	Takes user to Events page
5	Copy	Disclaimer copy

• HCP Websites

• Genzyme Websites

• Genzyme Corporate

› Medication Guide

› Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

TYPE SIZE: A A A

SHARE

ABOUT LEMTRADA

WHAT TO EXPECT

RESOURCES & SUPPORT

1

LEMTRADA SUPPORT AT

2

MS ONE TO ONE

3

4

Considering LEMTRADA or looking for more information? Start here. Our personalized patient support program, *MS One to One*® is always here to help. Sign up and access a world of support, including:

• Information and updates about LEMTRADA.

• A team of *MS One to One*® nurse experts to answer your questions.

• Insurance and cost support, as well as financial assistance\* for eligible patients that may include LEMTRADA at \$0 out-of-pocket cost through the LEMTRADA Copay Program†. Eligible patients may also receive up to \$100 for each day of infusion toward the cost of their LEMTRADA administration‡.

5

REGISTER NOW

7

LEMTRADA EVENTS

a

b

c

Attend free, local events about the latest in MS treatment

GET THE GUIDE

6

\* Patients who have coverage or prescriptions paid for in part or in full under Medicare, Medicaid, or other state of federally funded healthcare programs are not eligible.

† If you are not eligible for the LEMTRADA Copay Program and need help with out-of-pocket expenses, MS One to One can help review your coverage options. Depending on your specific situation, your MS One to One Nurse can direct you to other patient assistance programs that may offer you financial support.

‡ Treatment-related, out-of-pocket costs are not reimbursable in MA, MI, MN, or RI.

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:

• Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may lead to serious health problems and even death. If detected early, ITP is usually treatable. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms: easy bruising, bleeding from a cut that is hard to stop, heavier menstrual periods than normal, bleeding from your gums or nose that is new or takes longer than usual to stop, or small,scattered spots on your skin that are red, pink, or purple.

• Thyroid disorders. LEMTRADA may cause thyroid disorders, such as an overactive or under active thyroid gland.Thyroid disorders are common and generally manageable, even though they may require lifelong treatment.Call your healthcare provider if you have any of these symptoms: excessive sweating or feeling cold, unexplained weight loss or weight gain, eye swelling, nervousness, fast heartbeat,worsening tiredness, or newly occurring constipation.

• Kidney disease. LEMTRADA may cause a condition known as antiglomerularbasement membrane(anti-GBM) disease. This can result in severe damage to the kidneys. It can also damage the lungs, although this was not seen in clinical trials withLEMTRADA. If untreated, anti-GBMdisease can cause kidney failure requiring chronic dialysis or transplant,and may lead to death. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms:red or tea-colored urine, swelling in your legs or feet, or coughing up blood.

Monitoring. It is important that you follow your healthcare provider’s request for monthly blood and urine tests, so that if side effects associated with LEMTRADA occur, they can be recognized early and treated promptly. It is very important that you continue to have these tests for 4 years after your last LEMTRADA infusion, even if you are feeling well, have no side effects, and your MS symptoms are under control. Some side effects may occur many years after your LEMTRADA treatment and may be life-threatening,so it is very important to continue to follow your healthcare provider’s request for regular blood and urine tests and watch out for any symptoms.

Serious infections. LEMTRADA lowers the number of some white blood cells fora period of time after treatment. People with decreased white blood cells may have an increased risk for developing serious infections. Call your healthcare provider right away if you have any signs or symptoms of infection, such as fever,chills, or swollen glands.

LEMTRADA is only available through theAllianceSM Program, which is a restricted distribution program. This means that only prescribers, patients, and healthcare facilities enrolled in the Alliance Program can prescribe, receive, and infuseLEMTRADA. To receive LEMTRADA,you must talk to your healthcare provider and understand the

TERMS & CONDITIONS • PRIVACY POLICY • CONTACT

SITEMAP • UNSUBSCRIBE

1	Copy	Title
2	Graphic	MS 1 to 1 logo
3	Graphic	Background image
4	Copy	Headline
5	Navigation	Register
6	Copy	Explanatory copy
7	Lemtrada Events	
7a	Graphic	
7b	Copy	Body copy
7c	Navigation	Takes user to Events page
8	Copy	Disclaimer copy

HCP Websites

Genzyme Websites

Genzyme Corporate

Medication Guide

Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

TYPE SIZE: A A A

SHARE

PRINT

ABOUT LEMTRADA

GETTING STARTED

RESOURCES & SUPPORT

1

SIGN UP FOR LEMTRADA INFORMATION, EXPERT HELP, AND MORE

2

Get comprehensive, personalized assistance from our LEMTRADA patient support program. MS One to One

3

All form fields are required :

4

First Name

5

Last Name

6

Email Address

7

Re-enter Email Address

8

Address Line 1

9

Address Line 2

10

City

11

State

12

Zip

13

Birthdate :

14

Month

15

Day

16

Year

17

Please select which best applies to you :

18

☐

I am a person with multiple sclerosis (MS) interested in learning more

19

20

☐

I have been prescribed LEMTRADA

21

22

☐

I care for a person with MS

23

24

☐

I care for a person prescribed LEMTRADA

25

26

Are you currently on medication for MS

27

☐ Yes

☐ No

28

29

Approximate start date of treatment

30

Month

31

Day

32

Year

33

[I am a doctor looking for information on LEMTRADA](#)

34

Would you like an MS One to One® Nurse to call you?

35

☐

Yes

36

37

☐

By checking this box, you agree that Genzyme, its affiliates, and agents (such as third-party business partners) can: send you information and multiple sclerosis and Genzyme products, promotions, services, and research studies: ask your opinion about such information and topics, including market research and disease-related surveys: and share the information you provide with one another to perform these activities, and to de-identify it for use in performing research, education, business analytics, marketing studies, and other commercial purposes. Your information will not be sold to any third party. You may opt out of continued receipt of such communications at any time by call 1-855-576-6326.

38

39

SUBMIT

CONTACT

SITEMAP

TERMS & CONDITIONS

PRIVACY POLICY

UNSUBSCRIBE

1	Copy	Title
2	Copy	Body copy
3	Copy	Header
4	Text entry field	First name
5	Text entry field	Last name
6	Text entry field	Email address
7	Text entry field	Re-enter email address
8	Text entry field	Address Line 1
9	Text entry field	Address Line 2
10	Text entry field	City
11	Drop down field	City
12	Text entry field	Zip
13	Copy	Title
14	Drop down field	Month
15	Drop down field	Day
16	Drop down field	Year

17	Copy	Title
18	Form element	Radio button
19	Copy	Question copy
20	Form element	Radio button
21	Copy	Question copy
22	Form element	Radio button
23	Copy	Question copy
24	Form element	Radio button
25	Copy	Question copy
26	Copy	Question copy, optional, appears only if user chooses #18
27	Form element	Radio button
28	Form element	Radio button

29	Copy	Question copy, optional, appears only if user chooses #22 or #24
30	Drop down field	Month
31	Drop down field	Day
32	Drop down field	Year
33	Navigation	Link to HCP site, link spawns interstitial overlay please refer to appendix A
34	Copy	Title
35	Form element	Check box
36	Copy	
37	Form element	Check box
38	Copy	

• HCP Websites

• Genzyme Websites

• Genzyme Corporate

▸ Medication Guide

▸ Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

TYPE SIZE: A **A** A

 SHARE

PRINT

ABOUT LEMTRADA

GETTING STARTED

RESOURCES & SUPPORT

1

SIGN UP FOR LEMTRADA INFORMATION, EXPERT HELP, AND MORE

2

Get comprehensive, personalized assistance from our LEMTRADA patient support program. MS One to One

Thank you! 

3

Your information has been received

CONTACT • SITEMAP

TERMS & CONDITIONS • PRIVACY POLICY • UNSUBSCRIBE

1	Copy	Title
2	Copy	Body copy
3	Copy	Confirmation copy

• HCP Websites

• Genzyme Websites

• Genzyme Corporate

› Medication Guide

› Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

TYPE SIZE: A A A

SHARE

PRINT

ABOUT LEMTRADA

GETTING STARTED

RESOURCES & SUPPORT

1

LEMTRADA EVENTS

2

Sis dienirt ernulia escerfec tescrem alicto con diemus, nostiac virmilinum seniaestrem, cribulis?  
Opone omnimus, nostus, conlos cae culvirta, nos cludam in acer perce pecultorsus interce rar

3

4

FIND AN EVENT

5

Enter new zip code :

6

7

FIND

8

9

10

Sort by : 

Date

Distance

11

FEATURED EVENT

12

OCTOBER

04

12:30 PM | THU

a

b

TITLE

Moluptio rerspitat volent omnis sita conecerum faccusam fuga. Bor sequam facculparum quam

c

SPEAKER

: Name Lastname

d

LOCATION

: Location, City, State

e

Os sitas doluptas enis rereribus vellabo. Pictur?  
Rat eos eiur auda velleces mil et, optur? Musae num facienit fugitis sequia num volo quia doloris si doluptat. **LEARN MORE**

f

g

04

spots available

h

65

miles away

i

REGISTER

OCTOBER

04

12:30 PM | THU

TITLE

Moluptio rerspitat volent omnis sita conecerum faccusam fuga. Bor sequam facculparum quam

SPEAKER

: Name Lastname

LOCATION

: Location, City, State

Os sitas doluptas enis rereribus vellabo. Pictur?  
Rat eos eiur auda velleces mil et, optur? Musae num facienit fugitis sequia num volo quia doloris si doluptat. **LEARN MORE**

04

spots available

65

miles away

REGISTER

OCTOBER

04

12:30 PM | THU

TITLE

Moluptio rerspitat volent omnis sita conecerum faccusam fuga. Bor sequam facculparum quam

SPEAKER

: Name Lastname

LOCATION

: Location, City, State

Os sitas doluptas enis rereribus vellabo. Pictur?  
Rat eos eiur auda velleces mil et, optur? Musae num facienit fugitis sequia num volo quia doloris si doluptat. **LEARN MORE**

04

spots available

65

miles away

REGISTER

INDICATION

LEMTRADA™ (alemtezumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS). 

13

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:  
• Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may

CONTACT

• SITEMAP

TERMS & CONDITIONS

• PRIVACY POLICY

• UNSUBSCRIBE

1	Copy	Headline
2	Copy	Body copy
3	Graphic	Icon
4	Copy	
5	Copy	
6	Text entry field	
7	Call to action	Find
8	Copy	
9	Call to action	Sort by date
10	Call to action	Sort by distance
11	Copy	Headline
12	Event information lockup	
12a	Copy	Time/Date stamp
12b	Copy	Title
12c	Copy	Speaker
12d	Copy	Location

12e	Copy	Body copy
12df	Navigation	Learn more about the event
12g	Dynamic copy	Number of spaces available
12h	Dynamic copy	Distance
12i	Call to action	Register for the event
13	Copy	Disclaimer copy



HCP Websites

Genzyme Websites

Genzyme Corporate

Medication Guide

Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

TYPE SIZE: A A A

SHARE

PRINT

ABOUT LEMTRADA

GETTING STARTED

RESOURCES & SUPPORT

1

a

MONTH

b

15

c

11.30 PM

d

THURSDAY

2

9

SPOTS

AVAILABLE

3

65

miles away

4

Main topic of the event &

Secondary Topic if applicable

5

MAIN TOPIC : DAt incidem etur sinctur iatur, occus,

sed earum repelitis modio eiur recus expliquae del mo

comnimos autemquod mi, nonsenimilla sitia atis et odi

officabo. Ucimagnam re, ulla invene minimax imiliqui

doloribeatus molorun tintet fugiaecto quidebit, si imi,

secte ea plaut modita quam accum destinu lluptatur, ut

reicienem il il endi qui am ullupta quoditium e

6

7

CHEZ GEORGE

2100 SMITHVILLE RD.

VALLEY FORGE, PA

08724

8

SPEAKERS

9

a

FIRST LASTNAME

KOL title if needed

Here is where you will find my bio in Luptae ex eiundam ilicia dolo ber-ro etur, nossecumquis andiatibus doluptaquos este quatustia

10

FIRST LASTNAME

Topic 2 title if needed

Here is where you will find my bio in Luptae ex eiundam ilicia dolo ber-ro etur, nossecumquis andiatibus doluptaquos este quatustia

11

a

✓

b

RSVP to Attend

c

First Name

d

Last Name

e

Email Address

f

Your ZIP code

g

☐ I am a person with multiple scle-rosis (MS) interested in learning more

h

☐ I have been prescribed LEMTRADA

i

☐ I care for a person with MS

j

☐ I care for a person prescribed LEMTRADA

k

☐ By checking this box, you agree that Genzyme, its affiliates, and agents (such as third-party business partners) can: send you information and multiple scle-rosis and Genzyme products, promo-tions, services, and research studies: ask your opinion about such information and topics, including market research and disease-related surveys: and share the information you provide with one another to perform these activities, and to de-identify it for use in performing research, education, business analytics, marketing studies, and other commercial purposes. Your information will not be sold to any third party. You may opt out of continued receipt of such communi-cations at any time by call 1-855-576-6326.

l

Number of Guests

Select

Share event with a friend:

Email Address

SUBMIT

13

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:

• Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may lead to serious health problems and even death. If detected early, ITP is usually treatable. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms: easy bruising, bleeding from a cut that is hard to stop, heavier menstrual periods than normal, bleeding from your gums or nose

CONTACT • SITEMAP

TERMS & CONDITIONS • PRIVACY POLICY • UNSUBSCRIBE

1	Date Time lockup		8	Copy	Title	11h	Copy	Question
1a	Dynamic copy	Month	9	Speaker presentation layer		11i	Form element	Radio button
1b	Dynamic copy	Date	9a	Graphic	Optional photo-graph	11j	Copy	Question
1c	Dynamic copy	Time	9b	Copy	First and last name	11k	Form element	Radio button
1d	Dynamic copy	Day	9c	Copy	Title, description	11l	Copy	Question
2	Dynamic copy	# of available spots left avail-able (3rd party vendor info)	9d	Copy	Optional biography	11m	Form element	Radio button
3	Dynamic copy	Number of miles in disance	10	Topic 1 speaker presentation layer	Follows same format as 9	11n	Copy	Question
4	Copy	Title	11	RSVP lockup		11o	Form element	Check box
5	Copy	Body copy	11a	Graphic		11p	Copy	
6	Navigation	Google map graphic, will launch either app or web-site depending on system preferences (3rd party vendor info)	11b	Title		11q	Copy	
7	Copy	Location	11c	Text entry	First name	11r	Form element	Drop down box
			11d	Text entry	Last name	11s	Copy	
			11e	Text entry	Email address	11t	Form element	Text entry box
			11f	Text entry	Zip code	11u	Call to action	Submit
			11g	Form element	Radio button	12	Copy	Disclaimer copy



• HCP Websites

• Genzyme Websites

• Genzyme Corporate

› Medication Guide

› Full Prescribing Information

LOGO

IMPORTANT SAFETY INFORMATION : Quiati cus enet ullestrum, occum excer-runt faceprate voluptur, nobisin etur. Ant laborione pliquo vendae minvent hi-tions errorem ipit la porescid quas doluptas molestr umquide rciliquo bea.  
[Full Important Safety Information](#)

TYPE SIZE: A A A

SHARE

PRINT

ABOUT LEMTRADA

GETTING STARTED

RESOURCES & SUPPORT

1

HELPFUL RESOURCES

2

Sis dienirt ernulia escerfec tescrem alicto con diemus, nostiac virmilinum seniaestrem, cribulis?  
Opone omnimus, nostus, conlos cae culvirta, nos cludam in acer perce pecultorsus interce rar

3

TITLE

4

www.link.com

Ent, non net etur sunt aute sim volorem harchit venimaio. Uciam etur aut as quist velignit ea voluptas dendit, ut qui ut eos consequis volupta quias ant a non plit, corectam aut quam fugitaturero berovitat.  
Iquidelictia cullant volorit atecaer ecerrov itinciis dolore plitissima ipissum, vororio nsequissus rem resequa eptatem ipsam, ommolec tatendebit, consece atempos adis es ute volorumquod exped qui dolla nonsequis exerumenis q

5

TITLE

www.link.com

Ent, non net etur sunt aute sim volorem harchit venimaio. Uciam etur aut as quist velignit ea voluptas dendit, ut qui ut eos consequis volupta quias ant a non plit, corectam aut quam fugitaturero berovitat.  
Iquidelictia cullant volorit atecaer ecerrov itinciis dolore plitissima ipissum, vororio nsequissus rem resequa eptatem ipsam, ommolec tatendebit, consece atempos adis es ute volorumquod exped qui dolla nonsequis exerumenis q

TITLE

www.link.com

Ent, non net etur sunt aute sim volorem harchit venimaio. Uciam etur aut as quist velignit ea voluptas dendit, ut qui ut eos consequis volupta quias ant a non plit, corectam aut quam fugitaturero berovitat.  
Iquidelictia cullant volorit atecaer ecerrov itinciis dolore plitissima ipissum, vororio nsequissus rem resequa eptatem ipsam, ommolec tatendebit, consece atempos adis es ute volorumquod exped qui dolla nonsequis exerumenis q

6

LEMTRADA EVENTS

Attend free, local events about the latest in MS treatment

GET THE GUIDE

7

ms one to one

Get information, resources and more from LEMTRADA support at MS One to One®.

LEARN MORE

INDICATION

LEMTRADA™ (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious autoimmune side effects, including blood, thyroid, and kidney conditions. No one can predict who will develop autoimmune side effects. Regular laboratory tests and awareness of the signs and symptoms can help your healthcare provider detect, diagnose, and treat these side effects:

• Immune thrombocytopenic purpura(ITP, or low platelets). LEMTRADA may cause a serious condition known as ITP. ITP can cause severe bleeding that, if untreated, may lead to serious health problems and even death. If detected early, ITP is usually treatable. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms: easy bruising, bleeding from a cut that is hard to stop, heavier menstrual periods than normal, bleeding from your gums or nose that is new or takes longer than usual to stop, or small,scattered spots on your skin that are red, pink, or purple.

• Thyroid disorders. LEMTRADA may cause thyroid disorders, such as an overactive or under active thyroid gland.Thyroid disorders are common and generally manage-able, even though they may require lifelong treatment.Call your healthcare provider if you have any of these symptoms: excessive sweating or feeling cold, unexplained weight loss or weight gain, eye swelling, nervousness, fast heartbeat,worsening tiredness, or newly occurring constipation.

• Kidney disease. LEMTRADA may cause a condition known as antiglomerularbasement membrane(anti-GBM) disease. This can result in severe damage to the kidneys. It can also damage the lungs, although this was not seen in clinical trials withLEMTRADA. If untreated, anti-GBMdisease can cause kidney failure requiring chronic dialysis or transplant,and may lead to death. Call your healthcare provider immediately or seek immediate medical help if you have any of these signs or symptoms:red or tea-

CONTACT • SITEMAP

TERMS & CONDITIONS • PRIVACY POLICY • UNSUBSCRIBE

1	Copy	Title
2	Copy	Body copy
3	Copy	Title
4	Navigation	Hyperlink to associated site, link spawns interstitial overlay please refer to appendix A
5	Copy	Body copy
6	Lemtrada lockup	
6a	Graphic	
6b	Copy	Body copy
6c	Navigation	Takes user to Events page
7	MS 1 to 1 lockup	
7a	Graphic	
7b	Copy	Body copy
7c	Navigation	Takes user to MS 1 to 1 page
8	Copy	Disclaimer copy

This information is intended for  
US Health Care Professionals

I am a US Health Care / Medical Professional >

I am not a US Health Care / Medical Professional >

Interstitial for any Health Care Provider Link

You Are About to Leave Lemtrada.com

Genzyme Corporation does not review or control the content of non-Genzyme websites, and this hyperlink does not constitute an endorsement by Genzyme of the site's content. Genzyme's privacy procedures do not apply to the owners of a non-Genzyme website.

CONTINUE >

CANCEL >

Interstitial for any any outside link